

BMJ Open

The prevalence of metabolic syndrome and diabetes mellitus in Sami and Norwegian populations. The SAMINOR study.

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2015-009474
Article Type:	Research
Date Submitted by the Author:	01-Aug-2015
Complete List of Authors:	Broderstad, Ann Ragnhild; Uit the Arctic University of Norway, Centre for Sami Health Research, Faculty of Health Melhus, Marita; Uit the Arctic University of Norway, Centre of Sami Health research, Faculty of Health
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Diabetes and endocrinology, Epidemiology, Public health, Nutrition and metabolism
Keywords:	Hypertension < CARDIOLOGY, General diabetes < DIABETES & ENDOCRINOLOGY, General endocrinology < DIABETES & ENDOCRINOLOGY, Lipid disorders < DIABETES & ENDOCRINOLOGY, EPIDEMIOLOGY

SCHOLARONE™
Manuscripts

Original Article**The prevalence of metabolic syndrome and diabetes mellitus in Sami and Norwegian populations. The SAMINOR study.****Authors:**Ann Ragnhild Broderstad ^{1,2}Marita Melhus ¹

1. Centre for Sami Health Research, University of Tromsø The Arctic University of Norway

2. Medical Department, University Hospital of North Norway, Harstad

Contact details:

Ann Ragnhild Broderstad

Centre for Sami Health Research

University of Tromsø The Arctic University of Norway

N-9037 Tromsø

Norway

e-mail: Ann.Ragnhild.Broderstad@uit.no

Telephone +47 776 44000 / +47 78 46 89 00 Fax +47 78 46 89 10/ +47 76985021

Running head; Metabolic syndrome and diabetes among Sami and non-Sami

Keywords Metabolic, obesity, Sami, SAMINOR, diabetes

Words 2964

Tables 3

Figures 2

Abstract

Background

Metabolic syndrome (MetS) is generally recognized as a reliable long-term predictor of adverse health outcomes known to elevate risks of developing type 2 diabetes mellitus. Elevated prevalence rates of MetS and chronic lifestyle diseases have been documented in different indigenous groups. The Sami people are the indigenous group of North Norway. Therefore we wanted to evaluate the prevalence of MetS and diabetes mellitus in relation to ethnicity.

Material and methods

SAMINOR is a population based study of health and living conditions in areas home to both Sami and non-Sami populations in North Norway. The survey was carried through in 2003 – 2004. In total, 16,538 males and females aged 36-79 participated and gave informed consent for medical research. Sami affiliation was reported in 5141 people (35 percent).

Results

The study demonstrated a high prevalence of overweight and obesity in this population. Obesity and central obesity was most pronounced in Sami women. The prevalence of self-reported diabetes type 2 was 4.3 percent for men and 4.4 percent for women. Almost 19 percent of women and 12 percent of men had MetS.

Conclusions

The prevalence of MetS was higher in Sami females than in non-Sami females. Non-Sami males showed higher overall prevalence of MetS. The prevalence of MetS increased significantly by age in both ethnic groups. It was therefore somewhat surprising that, irrespective of age, ethnicity seemed not to influence diabetes prevalence.

Strengths and limitations of this study

- The SAMINOR study is the first survey to report on the prevalence of diabetes and MetS in a large geographic area of North Norway including both the indigenous and the non-indigenous population.
- The large sample size allowed for detailed analysis of diabetes and MetS in Sami and non-Sami populations of rural North Norway.
- The survey has a relatively high response rate.
- Categorizing people based on ethnicity is a contentious practice. Different studies use different criteria of ethnicity, which makes it difficult to compare results.
- Cross-sectional data cannot assess the effect of lifestyle on the incidence of MetS, and longitudinal cohort studies are therefore needed

The prevalence of metabolic syndrome and diabetes mellitus in Sami and Norwegian populations. The SAMINOR study.

Introduction

Chronic disease has become a global problem and a burden on health care services, reaching epidemic proportions. In Norway, as well as internationally, the great majority of patients in health care systems are living with chronic disease.[1-2] Cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), cancer and chronic obstructive pulmonary disease (COPD) are the most common causes of hospitalization and premature death.[3] Unfavorable health factors such as obesity, insulin resistance, dyslipidemia and hypertension are known to elevate risks of developing CVD and T2DM. Metabolic syndrome (MetS) indicates a cluster of these risk factors. [4-5] MetS is generally recognized as a reliable long-term predictor of adverse health outcomes.[6] Further, MetS has been recognized as a growing, global public health problem. [7] In addition, several studies demonstrate MetS to be associated with elevated cancer risk.[8-9]

However, information on the prevalence of chronic disease in various ethnicities of North Norway remains sparse. The Sami, Kven and Norwegian ethnic groups are recognized as having inhabited the region in centuries; the Norwegian government acknowledges the Sami people as the indigenous people of Norway.

Several epidemiological studies have documented elevated prevalence rates for chronic lifestyle diseases in a number of different minority groups.[5, 10 -11] Although such disorders have emerged quite recently in indigenous populations — mainly due to changes in lifestyle and diet — they are, however, prevalent in several indigenous populations.[12-13]

Publications from the SAMINOR study of North Norway demonstrate that the prevalence of obesity was high in the survey population, especially among Sami women.[14-15] However, information relating specifically to the Sami population remains insufficient.

1
2
3 In order to evaluate the health of indigenous and non-indigenous populations of Norway
4 (inhabiting the same geographic area) it was necessary to conduct an epidemiological survey.
5
6
7 The SAMINOR study provides unique information on lifestyle diseases and risk factors. The
8
9
10 present study aims to evaluate the prevalence of MetS and diabetes mellitus in Sami and non-
11
12 Sami populations residing in selected areas of North Norway.

13 14 **Methods**

15 16 *The SAMINOR study*

17
18 The cross-sectional data is derived from the SAMINOR study of 2003-2004 (SAMINOR 1).
19
20 The SAMINOR study was conducted by The Centre for Sami Health Research, Department
21
22 of Community Medicine, UiT The Arctic University of Norway, in collaboration with the
23
24 National Screening Program for Cardiovascular Diseases. The survey is described in detail
25
26 elsewhere.[16]
27
28

29 30 *The study sample*

31
32 All eligible residents aged 30 and 36-79 years registered in the Central Population Register in
33
34 24 selected municipalities were invited regardless of ethnic background (n=27,987). Due to a
35
36 low response rate among those aged 30 years, our analyses were restricted to the age interval
37
38 36-79 years (n=27,151). In total, 16,538 males and females aged 36-79 participated and gave
39
40 informed consent for medical research. The response rate was 61 per cent. Data was obtained
41
42 from physical tests and blood samples. Information on ethnicity, and the different diagnostic
43
44 tools for MetS, were available for 15,112 participants.
45
46

47 48 *Questionnaire design*

49
50 Information regarding ethnicity, disease and lifestyle were collected using two self-
51
52 administrated questionnaires. Ethnicity was measured using the following questions: "*What*
53
54 *language(s) do/did you, your parents and your grandparents use at home?*" The questions
55
56 were to be answered separately for each relative. The available responses were: "Norwegian",
57
58
59
60

1
2
3 “Sami”, “Kven” and “Other”. Multiple answers were allowed. Providing the same response
4 options we also asked: “*What is your, your father’s and your mother’s ethnic background?*”

5
6
7 The respondents also reported whether they considered themselves to be Norwegian, Sami,
8 Kven or other (self-perceived ethnicity). Based on these variables we generated two
9 categories of ethnicity: “Sami” and “Non-Sami”. Participants reporting at least one Sami
10 identity mark (Sami language spoken by the respondent or at least one parent or grandparent,
11 or Sami ethnic background or self-perceived Sami ethnicity) were placed in the category
12 “Sami”. The “Non-Sami” comprise the remainder of the participants.
13
14

15
16
17 The study was accredited by the Regional Board of Research Ethics in Northern Norway, and
18 by the Board's Sami Consultant. The survey is in accordance with the Helsinki Declaration of
19 1975. The National Data Protection Authority (*Datatilsynet*) approved the use of personal
20 information.
21
22

23 *Screening*

24
25 Due to the large size of the study sample participants were examined at different times of day.
26 This meant that it was not possible to ask participants to be fasting prior to arrival. Non-
27 fasting blood samples were obtained at the research station. Blood samples were drawn by
28 venopuncture at normal venous pressure in sitting position. Serum was separated at the station
29 within 1.5 hours. Serum was sent by overnight mail to laboratories in Oslo and Tromsø. The
30 laboratory analyses are described in detail elsewhere.[17]
31
32

33
34 Body mass index (BMI) was based on measurements of weight and height, and expressed as
35 body weight in kilograms/(body height in meters)². BMI categories were defined according to
36 guidelines from The World Health Organization (WHO); 'underweight' corresponding to a
37 BMI<18.5 kg/m², 'standard weight' in the range 18.5–24.9 kg/m², 'overweight' in the range 25
38 – 29.9 kg/m² and 'obese' ≥30 kg/m². [18]
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Waist circumference (WC), which is used to identify abdominal obesity, was measured (to the
4 nearest centimeter) at the umbilicus with the participant standing erect. Two different WC
5 cut-off values were applied to define abdominal obesity to enable the comparison of how the
6 corresponding values influenced the subsequently calculated prevalence of MetS. The US
7 National Institute of Health (NIH) Clinical Practice Guidelines defines central/abdominal
8 obesity as $WC \geq 102$ cm in males and $WC \geq 88$ cm in females.[19] In addition, abnormal WC
9 for Euroid males are ≥ 94 cm and for females ≥ 80 cm. These figures are based on cross-
10 sectional data from Euroids and were included in the analyses.[18,20]

11
12 Trained personnel measured blood pressure, using Dinamap –R. automatic device.

13
14 Measurements were initiated after subjects had been seated for two minutes with their arms
15 resting on a table. Blood pressure was measured three times, with one- minute intervals. The
16 mean value of the second and third reading was used in the analysis.

17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Diabetes mellitus

Because all blood samples in the SAMINOR study were non-fasting, we used random plasma
glucose ≥ 11.1 mmol/L, in addition to self-reported diabetes and information about anti-
diabetic medication from a questionnaire to define diabetes mellitus. The question about
diabetes mellitus was; “Do you have or have you had diabetes?” The available responses
were “Yes” or “No”. Missing values were classified as “No”. In the absence of oral glucose
tolerance tests we used random plasma glucose ≥ 11.1 mmol/l as a substitute for elevated oral
glucose tolerance test.

Metabolic syndrome

Several attempts have been made at developing diagnostic criteria for the definition of MetS.
[21-23] In 2004, the International Diabetes Federation (IDF), the WHO and the National
Cholesterol Education Program Third Adult Treatment Panel (ATP III) produced a consensus
statement on the definition of MetS.[24] The latter definition requires central obesity and cut-

1
2
3 off points to be specified according to gender and ethnicity. Central obesity is most commonly
4
5 measured by WC; cut-off values are based on cross-sectional studies conducted in Europe,
6
7 The United States and Asia.[18-20, 25] The diagnostic tools are intended for clinical and
8
9 research purposes. The definition of MetS used in this article adheres to the IDF MetS
10
11 worldwide definition,[24]: Central obesity plus any two of four additional factors; Elevated
12
13 triglyceride level > 1.7 mmol/l, reduced HDL-cholesterol < 1.03 mmol/l in males and < 1.29
14
15 mmol/l in females, elevated blood pressure (systolic BP \geq 130 or diastolic BP \geq 85 mmHg)
16
17 and elevated fasting plasma glucose \geq 11.1 mmol/l or previously diagnosed type 2 diabetes.
18
19

20 21 *Statistical analyses*

22
23 All analyses were stratified by gender. Sample characteristics were presented separately by
24
25 gender and ethnicity as mean values for continuous variables with corresponding 95 per cent
26
27 confidence intervals. Analyses of variance (ANOVA) were used for tests of ethnic
28
29 differences (Table 2). Differences according to diabetes mellitus and Mets prevalence were
30
31 tested by Chi-square tests (Tables 3 and 4). MetS prevalence was also stratified by age (Table
32
33 4). Logistic regression analyses were used to test for age influence on MetS with age as a
34
35 continuous variable (Table 4). Test for differences in number of risk markers between Sami
36
37 and non-Sami were tested by Chi-square tests (Table 5).
38
39

40
41 We used the SAS statistical software package, version 9.3 (SAS Institute Inc., Cary, NC,
42
43 USA).
44
45

46 47 **Results**

48
49 The current analysis involved a total of 7,822 female and 7,290 male participants. Sami
50
51 affiliation was reported by 5,141 participants (34 per cent). Table 1 shows gender-specific and
52
53 ethnicity-specific characteristics at screening.
54
55
56
57
58
59
60

Table 1 Sample characteristics by sex and ethnic group. (N= 15 112)

Men	Sami (N=2559)	Non-Sami (N=4731)	p-value ²
	Mean (95 % CI) ¹		
Age (yr)	55.0 (54.8-55.1)	54.8 (54.7-54.9)	0.584
Height (cm)	170.0 (170.0-170.2)	175.7 (175.6 – 175.8)	<0.0001
Weight (kg)	80.6 (80.4 – 80.7)	85.1 (85.0 – 85.3)	<0.0001
BMI (kg/m ²)	27.8 (27.7-27.9)	27.5 (27.5 – 27.6)	0.009
WC (cm)	93.2 (93.0 – 93.3)	95.0 (94.9 – 95.2)	<0.0001
Non-fasting glu (mmol/L)	5.8 (5.8- 5.8)	5.8 (5.7 – 5.8)	0.313
HDL-cholesterol (mmol/l)	1.27 (1.26 – 1.28)	1.25 (1.25 – 1.26)	0.115
LDL-cholesterol (mmol/L)	3.87 (3.86 – 3.89)	3.80 (3.79 – 3.81)	0.004
Cholesterol (mmol/l)	5.98 (5.96- 5.99)	5.90 (5.90 – 5.90)	0.001
Triglycerids (mmol/l)	1.86 (1.85 – 1.88)	1.86 (1.85 – 1.88)	0.970
Systolic BT (mmHg)	135 (135 – 135)	134 (134 -134)	0.168
Diastolic BT (mmHg)	78 (78 -78)	78 (78 – 78)	0.182
Women	Sami (N=2581)	Non-Sami (N=5241)	p-value
	Mean (95 % CI) ¹		
Age (yr)	54.2 (54.1 – 54.4)	54.5 (54.4 – 54.6)	0.277
Height (cm)	157.3 (157.2 – 157.4)	162.6 (162.6 – 162.7)	<0.0001
Weight (kg)	69.7 (69.6 – 69.9)	72.1 (71.9 -72.2)	<0.0001
BMI (kg/m ²)	28.2 (28.1 – 28.3)	27.3 (27.2 – 27.3)	<0.0001
WC (cm)	86.0 (85.9 – 86.2)	85.5 (85.4 – 85.6)	0.053
Non-fasting glu (mmol/L)	5.66 (5.63 – 5.68)	5.57 (5.55 – 5.58)	0.018
HDL-cholesterol (mmol/l)	1.45 (1.44 – 1.45)	1.49 (1.49 – 1.50)	<0.0001
LDL-cholesterol (mmol/L)	3.82 (3.81 – 3.83)	3.81 (3.80 – 3.82)	0.707
Cholesterol (mmol/l)	5.98 (5.96 – 5.99)	5.99 (5.98 – 6.00)	0.617
Triglycerids (mmol/l)	1.54(1.56 – 1.59)	1.53 (1.52 – 1.54)	0.044
Systolic BT (mmHg)	130 (129 – 130)	130 (130 -131)	0.125
Diastolic BT (mmHg)	72 (72 -72)	73 (73 -73)	0.008

¹ 95% confidence interval² test of differences , ANOVA, for between Sami versus non-Sami

The mean BMI was greater in Sami males, whereas the mean WC was greater in non-Sami males. Sami females, however, showed significantly greater values for mean BMI, WC and lipids.

Table 2 shows the prevalence of diabetes in Sami and non-Sami participants.

Table 2. Prevalence of diabetes mellitus in the SAMINOR study (N=15112)

	Sami (N=2559)		Non-Sami (N=4731)		p-value ¹
	n	(%)	n	(%)	
Men					
Diabetes prevalence	132	(5.2)	212	(4.5)	0.05
Insulin treatment	13	(0.5)	31	(0.7)	
Tablet treatment	45	(1.8)	87	(1.8)	
Insulin and tablet treatment	25	(1.0)	21	(0.4)	
Non- treatment	49	(1.9)	73	(1.5)	
Women					
Diabetes prevalence	129	(5.0)	220	(4.2)	0.026
Insulin treatment	13	(0.5)	29	(0.6)	
Tablet treatment	61	(2.4)	71	(1.6)	
Insulin and tablet treatment	20	(0.8)	38	(0.7)	
Non- treatment	35	(1.4)	82	(1.6)	

¹ Chi-square test for differences in diabetes prevalence among Sami versus non-Sami

Based on information gathered in questionnaires in addition to random plasma glucose ≥ 11.1 mmol/l. Ethnicity appeared not to affect diabetes prevalence.

In Figures 1 (males) and 2 (females) the prevalence figures found — using the various MetS diagnostic tools — are presented.

1
2
3 -----Figure 1 -----
4
5
6

7 -----Figure 2 -----
8
9
10

11
12
13
14 The most prevalent risk marker for MetS (aside from central obesity) was the presence of
15 elevated systolic blood pressure and high triglyceride levels independent of gender and
16 ethnicity. In contrast, diabetes mellitus contributes the least to MetS for all groups, but was
17 however, more prevalent than in the general study population. Diabetes mellitus was also
18 most frequent in Sami participants relative to non-Sami participants.
19
20
21
22
23
24

25 Table 3 presents the prevalence of MetS according to WC cut-off points based on European
26 and NIH values.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 3. Prevalence of MetS among Sami and non-Sami, by age groups and gender. N= 15112 participants

	European cut off of WC		p-value ¹	NIH cut off of WC		p-value ¹
	Sami (N=650) n (%)	Non-Sami (N=917) n (%)		Sami (N=315) n (%)	Non-Sami (N=728) n (%)	
Men						
36-49 yr	194 (22.3)	429 (26.0)	0.038	89 (10.2)	203 (12.3)	0.118
50-59 yr	229 (27.2)	440 (29.7)	0.202	115 (13.7)	238 (16.1)	0.121
60-79 yr	227 (26.9)	489 (30.6)	0.055	111 (13.1)	287 (18.0)	0.002
p-value ²	0.029	<0.0001		0.05	<0.0001	
	Sami (N=790) n (%)	Non-Sami (N=1521) n (%)		Sami (N=588) n (%)	Non-Sami (N=1091) n (%)	
Women						
36-49 yr	232 (24.4)	369 (19.1)	0.006	161 (16.2)	263 (13.6)	0.056
50-59 yr	248 (31.5)	455 (29.4)	0.291	177 (22.5)	309 (20.0)	0.155
60-79 yr	310 (38.7)	697 (39.6)	0.641	250 (31.2)	519 (29.5)	0.393
p-value ²	0.004	<0.0001		<0.0001	<0.0001	

¹ Chi-square tests for differences in MetS prevalence of Sami versus non-Sami

² Age effect tested by logistic regression with age as a continuous variable

1
2
3 In each age bracket the results are stratified according to ethnicity (Sami and non-Sami).
4
5 Based on the European WC cut-off points, prevalence of MetS was higher in non-Sami
6
7 participants in the age bracket 36-49 years. However, when applying the NIH WC cut-off
8
9 point, a significantly lower prevalence was found for Sami males in the top age group.
10
11 Non-Sami males showed a higher overall prevalence of MetS (in comparison to Sami males)
12
13 for both WC cut-off values. In females ethnicity was not significant overall; however when
14
15 stratified by age, a significantly higher prevalence of MetS in the younger Sami females (in
16
17 comparison to non-Sami females) was found — when applying the European WC cut-off
18
19 value. The prevalence of MetS increased with age regardless of gender and ethnicity. The
20
21 proportion of women with all four risk markers was almost twice as large within the Sami
22
23 population (in comparison to non-Sami females) for both WC cut-off values (not shown). For
24
25 males, ethnicity appeared not to affect the number of risk markers found.
26
27
28
29
30
31

32 Discussion

33
34 The two different WC cut-off values greatly influenced the measured prevalence of MetS.
35
36 The present study demonstrates that ethnicity is a significant factor for MetS in participants
37
38 belonging to the lowest age bracket. In the case of males aged between 36 and 49, MetS is
39
40 less prevalent in the Sami population (in comparison to non-Sami). For females in the same
41
42 age bracket, however, MetS is more prevalent in the Sami population. When the NIH cutoffs
43
44 were used, we found that — in the highest age bracket — the non-Sami males showed
45
46 significantly higher prevalence of MetS in comparison to Sami males. The prevalence of
47
48 MetS increased significantly by age in both ethnic groups, regardless of which WC cut-off
49
50 values were used. However, ethnicity could not be established to affect diabetes prevalence.
51
52
53 In general, overweight and obesity are common among the participants in the SAMINOR
54
55 study. From earlier publications based on the SAMINOR study, central obesity has been
56
57
58
59
60

1
2
3 shown to be more common in Sami females.[15,26] General obesity in Sami females has also
4
5 been discussed by Njølstad et al (1998).[27] However, obesity rates were high in non-Sami
6
7 females as well.[14] For males, central obesity occurred more frequently in the non-Sami
8
9 population relative to the Sami population.[14-15]

10
11 MetS has several different definitions, making it difficult to directly compare and contrast
12
13 prevalence found in different surveys. WC is the most significant measurement of both central
14
15 obesity and fat distribution, according to The International Diabetes Federation (IDF).[28]

16
17 The group that produced the consensus statement on the definition of MetS in 2004
18
19 recommended that gender and ethnicity should be the basis for classification of cut-off points.
20
21 [24] The existing values are based on cross-sectional population survey data from the
22
23 respective countries. How to define the WC cut-off point in the various indigenous
24
25 populations has not yet been established; however, an immediate response would be to
26
27 perform cross-sectional population surveys within indigenous societies. In our study two
28
29 different cut-off points were used in order to facilitate comparison. The European cut-off
30
31 values doubled the prevalence of MetS in males and increased prevalence by more than 40 per
32
33 cent in females (compared to values found when applying NIH WC cut-off values). This was
34
35 the case in both ethnic groups. But the question of what the WC values should be in terms of
36
37 optimal prediction of prospective disease in the SAMINOR sample remains unanswered. A
38
39 follow-up study could provide better answers to questions regarding disease development.
40
41 Irrespective of cut-off values, elevated blood pressure was the most frequent MetS component
42
43 present in obese participants. These findings were also demonstrated in a collaborative
44
45 analysis of ten large cohort studies in Europe.[29] In the ten studies included, obesity
46
47 coincided with hypertension in up to 85 per cent of cases.
48
49

50
51 The presence of MetS, as well as its individual components, however, shows considerable
52
53 variance between populations. Several studies of MetS have been performed in circumpolar
54
55
56
57
58
59

1
2
3 areas, such as in indigenous peoples of Alaska, Canada and Greenland.[30-32] American
4
5 Indians and Aboriginal Canadians represent populations in which MetS, obesity and T2DM
6
7 are becoming more prevalent. [13,30] MetS is also frequently occurring in Greenland's Inuit
8
9 population.[32] A health survey in Greenland showed that central adiposity and obesity are
10
11 more prevalent in the Inuit population when compared to the corresponding Danish
12
13 population, but was not associated with the same degree of metabolic disturbance as in the
14
15 general Danish population.[33] Yet it is debatable which factors in the cluster of MetS are the
16
17 most significant in the development of chronic lifestyle diseases.
18
19

20
21 There is a significant relation between T2DM and MetS; the syndrome itself is not a disease,
22
23 but a rather strong indicator for developing diseases. Thus we prefer to include diabetes in this
24
25 article to demonstrate the link between the health indicator MetS and diabetes mellitus.[24] In
26
27 the SAMINOR study diabetes mellitus was identified using a questionnaire, in addition to
28
29 measured random plasma glucose ≥ 11.1 mmol/L in participants whom did not report diabetes
30
31 mellitus. As the study was epidemiologically designed conducting two-hour plasma glucose
32
33 tolerance tests was infeasible. The portable HbA1c instruments available in 2003-2004 were
34
35 inadequate for conducting HbA1C measurements at rural research stations. In addition, the
36
37 survey was performed in provincial areas with long distances to the medical laboratory.
38
39

40
41 Our analyses do not differentiate between type 1 and 2 diabetes mellitus due to insufficient
42
43 information provided by the questionnaire. However, eight of ten diabetes cases in Norway
44
45 are T2DM.[34] Also, globally, around 80 per cent of diabetes cases are T2DM,[35-37] giving
46
47 a prevalence rate of 8.3 per cent. This figure is expected to increase; mainly, this is associated
48
49 with T2DM due to lifestyle changes: about 90 per cent of future total diabetes cases are
50
51 expected to be T2DM. [36] Diabetes prevalence in our study was between four and five
52
53 percent, which is a lower rate than the prevalence rate found in the urban population residing
54
55 in 2007-2008 in the city of Tromsø (8.5%) [38]. This study encompassed participants aged
56
57
58
59
60

1
2
3 between 30 and 87, with a mean age of 61. However, in the Tromsø study, fasting plasma
4 glucose, two-hour plasma glucose and HbA1c was measured. It is therefore likely that the
5 present study underreports the diabetes prevalence.
6
7

8 9 *Strengths*

10 Our study is the first survey to report on the prevalence of diabetes and MetS in a large
11 geographic area of North Norway including both the indigenous and the non-indigenous
12 population. The large sample size allowed for detailed analysis of diabetes and MetS in Sami
13 and non-Sami populations of rural North Norway; it also reduces the influence of random
14 errors, which cannot fully be controlled for. The survey had a relatively high response rate.
15
16

17 Unquestionably, one of the strengths of the study is that clinical data — such as central
18 obesity (upon which MetS relies) — was collected by direct measurement and conducted by
19 trained personnel, providing reliable estimates of obesity prevalence in the participating
20 cohort.
21
22

23 *Limitations*

24 The cross-sectional study design is suitable for the examination of associations in order to
25 generate hypotheses that may be explored in longitudinal studies. Conversely, however, the
26 design prevents the establishment of causality. Due to the nature of the design, people with
27 severe disease may be missed because they are diseased at home, in long-term hospitalization
28 or having died in the time since the sample list was prepared (i.e., selection bias). On the other
29 hand, the healthy segments of the population tend to not participate in health screenings.
30
31

32 Categorizing people based on ethnicity is a contentious practice. Different studies use
33 different criteria of ethnicity, which makes it difficult to compare results.
34
35

36 In summary, cross-sectional studies may be used in the measurement of the burden of disease
37 in a population. However, cross-sectional data cannot assess the effect of lifestyle on the
38 incidence of MetS, and longitudinal cohort studies are therefore needed.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Conclusion

Without question, the prevalence rates for several negative health factors were high in the Sami and non-Sami population. Overweight and obesity were common, especially in the case of Sami females. In males the prevalence of MetS was higher in non-Sami males (aged between 36 and 49 year). The prevalence of MetS increased significantly by age in both ethnic groups, regardless of which WC cut-off points were used. The measured prevalence of MetS changes according to which WC cut-off values are applied. A cross-sectional survey cannot provide complete and absolute answers; a follow-up study using a longitudinal design is essential. Such a study can provide information on which WC cut-off values best predict disease in the Sami population of Norway.

Acknowledgements

We are indebted to the participants of the SAMINOR study, without whom our research would be impossible. We would also like to thank the staff at the Department of Clinical Chemistry, University Hospital of North Norway, for technical assistance and careful evaluation of blood samples.

Funding for this project was provided by the Norwegian Ministry of Health and Care Services.

Conflict of Interest:

The authors declare that they have no conflict of interest.

Data sharing

Extra data is available by emailing ann.ragnhild.broderstad@uit.no

Summary Box

What is already known on this subject?

In Northern Norway the burden of obesity are especially high among female. Highest prevalence has been demonstrated among the Sami women. In this study we therefore examined several other risk factors for developing lifestyle diseases.

1
2
3 *What this study adds?*

4 This study showed a high prevalence of the metabolic syndrome among the population in
5 north, independent of ethnic belonging. The burden of metabolic risk factors was highest
6 among women, especially Sami women. Self-reported diabetes was between four and five
7 percent which are slightly higher than the national prevalence rate. In the future, obesity and
8 other metabolic risk factors will contribute to increase burden of lifestyle diseases among the
9 Sami population. Two issues are therefore important to emphasize. Firstly, implement
10 preventive interventions in the multicultural communities, as well as highlight research
11 information to inhabitants and local and central authorities. Secondly, follow the health
12 situation in each community with longitudinal studies to evaluate the effect of preventive
13 efforts.
14
15
16
17
18
19
20
21
22
23

24 **Contributorship statement.**

25 The idea behind the study was conceived by Ann R Broderstad. Both authors participated in
26 the study concept and design. Ann R Broderstad drafted the manuscript. Both authors did the
27 analyses of the tables and figures. Both authors reviewed and approved the final version of the
28 manuscript.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Banatvala N, Donaldson L. Chronic diseases in developing countries. *Lancet* 2007; 370(9605): 2076-8.
2. Dale AC, Nilsen TI, Vatten L, Midthjell K, Wiseth R. Diabetes mellitus and risk of fatal ischaemic heart disease by gender: 18 years follow-up of 74,914 individuals in the HUNT 1 Study. *European heart journal* 2007; 28(23): 2924-9.
3. Parajuli R, Bjerkaas E, Tverdal A, et al. The increased risk of colon cancer due to cigarette smoking may be greater in women than men. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology* 2013; 22(5): 862-71.
4. Grundy SM, Brewer HB, Jr., Cleeman JI, et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. *Circulation* 2004; 109(3): 433-8.
5. Simmons RK, Alberti KG, Gale EA, et al. The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. *Diabetologia* 2010; 53(4): 600-5.

- 1
2
3 6. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated
4 with the metabolic syndrome: a summary of the evidence. *Diabetes care* 2005; 28(7): 1769-
5 78.
6
7
- 8
9 7. Goldstein MR, Mascitelli L, Pezzetta F. On treating metabolic syndrome: emphasise
10 lifestyle change. *The Lancet Oncology* 2010; 11(5): 415.
11
- 12 8. Ishino K, Mutoh M, Totsuka Y, Nakagama H. Metabolic syndrome: A novel high-risk
13 state for colorectal cancer. *Cancer letters* 2012.
14
- 15 9. Russo A, Autelitano M, Bisanti L. Metabolic syndrome and cancer risk. *European*
16 *journal of cancer* 2008; 44(2): 293-7.
17
- 18 10. Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in
19 worldwide populations. *Endocrinology and metabolism clinics of North America* 2004; 33(2):
20 351-75, table of contents.
21
- 22 11. Boyer BB, Mohatt GV, Plaetke R, et al. Metabolic syndrome in Yup'ik Eskimos: the
23 Center for Alaska Native Health Research (CANHR) Study. *Obesity* 2007; 15(11): 2535-40.
24
- 25 12. Liu J, Young TK, Zinman B, Harris SB, Connelly PW, Hanley AJ. Lifestyle variables,
26 non-traditional cardiovascular risk factors, and the metabolic syndrome in an Aboriginal
27 Canadian population. *Obesity* 2006; 14(3): 500-8.
28
- 29 13. Schumacher C, Ferucci ED, Lanier AP, et al. Metabolic syndrome: prevalence among
30 American Indian and Alaska native people living in the southwestern United States and in
31 Alaska. *Metabolic syndrome and related disorders* 2008; 6(4): 267-73.
32
- 33 14. Nystad T, Melhus M, Brustad M, Lund E. Ethnic differences in the prevalence of
34 general and central obesity among the Sami and Norwegian populations: the SAMINOR
35 study. *Scandinavian journal of public health* 2010; 38(1): 17-24.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 15. Broderstad AR, Melhus M, Lund E. Iron status in a multiethnic population (age 36-80
4 yr) in northern Norway: the SAMINOR study. *European journal of haematology* 2007; 79(5):
5 447-54.
6
7
8
9
10 16. Lund E, Melhus M, Hansen KL, et al. Population based study of health and living
11 conditions in areas with both Sami and Norwegian populations--the SAMINOR study.
12 *International journal of circumpolar health* 2007; 66(2): 113-28.
13
14
15
16 17. Nystod T, Utsi E, Selmer R, Brox J, Melhus M, Lund E. Distribution of apoB/apoA-1
17 ratio and blood lipids in Sami, Kven and Norwegian populations: the SAMINOR study. *Int J*
18 *Circumpolar Health* 2008; 67(1): 67-81.
19
20
21
22 18. Organization WH. *Obesity: Preventing and Managing the Global Epidemic*. . Geneva:
23 World Health Organization, 1997.
24
25
26
27 19. Janssen I, Peter T, Katzmarzyk PT, Ross R. Body Mass Index, Waist Circumference,
28 and Health RiskEvidence in Support of Current National Institutes of Health Guidelines *Arch*
29 *Intern Med*. 2002;162(18):2074-2079.
30
31
32
33 20. Lean ME, Han TS, Morrison CE. Waist circumference as a measure for indicating
34 need for weight management. *Bmj* 1995; 311(6998): 158-61.
35
36
37
38 21. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus
39 and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional
40 report of a WHO consultation. *Diabetic medicine : a journal of the British Diabetic*
41 *Association* 1998; 15(7): 539-53.
42
43
44
45
46
47 22. Balkau B, Charles MA. Comment on the provisional report from the WHO
48 consultation. European Group for the Study of Insulin Resistance (EGIR). *Diabetic medicine :*
49 *a journal of the British Diabetic Association* 1999; 16(5): 442-3.
50
51
52
53
54 23. Cleman JI. Executive summary of the third report of the National Cholesterol
55 Education Program (NCEP) expert panel on detection, evaluation, and treatment of high
56
57
58
59
60 21

- 1
2
3 blood cholesterol in adults (adult treatment panel III). *Journal of the American Medical*
4
5 *Association* 2001; 285(19): 2486 -97.
- 6
7 24. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome--a new world-wide definition. A
8
9 Consensus Statement from the International Diabetes Federation. *Diabetic medicine : a*
10
11 *journal of the British Diabetic Association* 2006; 23(5): 469-80.
- 12
13
14 25. Lin WY, Lee LT, Chen CY, et al. Optimal cut-off values for obesity: using simple
15
16 anthropometric indices to predict cardiovascular risk factors in Taiwan. *International journal*
17
18 *of obesity and related metabolic disorders : journal of the International Association for the*
19
20 *Study of Obesity* 2002; 26(9): 1232-8.
- 21
22
23 26. Nystad T, Melhus M, Brustad M, Lund E. Ethnic differences in the prevalence of
24
25 general and central obesity among the Sami and Norwegian populations: the SAMINOR
26
27 study. *Scand J Public Health*; 38(1): 17-24.
- 28
29
30 27. Njolstad I, Arnesen E, Lund-Larsen PG. Cardiovascular diseases and diabetes mellitus
31
32 in different ethnic groups: the Finnmark study. *Epidemiology* 1998; 9(5): 550-6.
- 33
34 28. Carr DB, Utzschneider KM, Hull RL, et al. Intra-abdominal fat is a major determinant
35
36 of the National Cholesterol Education Program Adult Treatment Panel III criteria for the
37
38 metabolic syndrome. *Diabetes* 2004; 53(8): 2087-94.
- 39
40
41 29. van Vliet-Ostaptchouk JV, Nuotio ML, Slagter SN, et al. The prevalence of metabolic
42
43 syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large
44
45 cohort studies. *BMC endocrine disorders* 2014; 14: 9.
- 46
47
48 30. Ley SH, Harris SB, Mamakeesick M, et al. Metabolic syndrome and its components as
49
50 predictors of incident type 2 diabetes mellitus in an Aboriginal community. *Cmaj* 2009;
51
52 180(6): 617-24.
- 53
54
55 31. Russell M, de Simone G, Resnick HE, Howard BV. The metabolic syndrome in
56
57 American Indians: the strong heart study. *J Cardiometab Syndr* 2007; 2(4): 283-7.
- 58
59
60

- 1
2
3 32. Jorgensen ME, Bjerregaard P, Gyntelberg F, Borch-Johnsen K. Prevalence of the
4 metabolic syndrome among the Inuit in Greenland. A comparison between two proposed
5 definitions. *Diabet Med* 2004; 21(11): 1237-42.
6
7
8
9
10 33. Jorgensen ME. Obesity and metabolic correlates among the Inuit and a general Danish
11 population. *Int J Circumpolar Health* 2004; 63 Suppl 2: 77-9.
12
13
14 34. Folkehelseinstituttet. Forekomst av diabetes - faktaark med helsestatistikk.
15 <http://www.fhi.no/artikler/?id=70814>
16
17
18 Folkehelseinstituttet; 2015.
19
20
21 35. Velho G, Froguel P, Mann J, Toeller M. Type 2 Diabetes. In: Ekoe J, Zimmet P,
22 Williams R, eds. *The Epidemiology of Diabetes mellitus*. Chichester, England: John Wiley &
23 Sons Ltd; 2001: 133-53.
24
25
26
27 36. Federation ID. IDF Diabetes Atlas. 6th edition [internet]. 2013.
28
29 <http://idf.org/diabetesatlas> (accessed May 4th 2013).
30
31
32 37. Gao XH, Winsey S, Li G, et al. HLA-DR and DQ polymorphisms in bullous
33 pemphigoid from northern China. *Clinical and experimental dermatology* 2002; 27(4): 319-
34
35
36
37 21.
38
39 38. Hutchinson MS, Joakimsen RM, Njolstad I, et al. Effects of Age and Sex on Estimated
40 Diabetes Prevalence Using Different Diagnostic Criteria: The Tromso OGTT Study.
41
42
43 *International journal of endocrinology* 2013; 2013: 613475.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Figure legends

-----Figure 1 colour -----

-----Figure 1 black and white -----


-----Figure 2 colour -----

-----Figure 2 black and white -----

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Open: first published as 10.1136/bmjopen-2015-009474 on 22 April 2016. Downloaded from <http://bmjopen.bmj.com/> on March 1, 2023 by guest. Protected by copyright.

Figure 2 . Prevalence of different risk markers in participants with MetS. Women .
N= 2311 Euro and N= 1679 NIH



162x165mm (300 x 300 DPI)

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	p 1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	P 2
Introductionp 4			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	P 4
Objectives	3	State specific objectives, including any prespecified hypotheses	P 5
Methods			
Study design	4	Present key elements of study design early in the paper	P 5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	p 5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	P 5-6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	p 6 -8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	P 6 -8
Bias	9	Describe any efforts to address potential sources of bias	P 6-8
Study size	10	Explain how the study size was arrived at	P 5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	p 8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	P 8
		(b) Describe any methods used to examine subgroups and interactions	P 8
		(c) Explain how missing data were addressed	P 8
		(d) If applicable, describe analytical methods taking account of sampling strategy	Not applicable
		(e) Describe any sensitivity analyses	Not done
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	P 8-9 and Table 1 Not done
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest	P 8- 9 and Table 1 No missing data in the further analyzes
Outcome data	15*	Report numbers of outcome events or summary measures	Table 1 p 8
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Table 2 p 10, table 3 p 12 fig 1 and 2 p 11 Not relevant
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Not done
Discussion			
Key results	18	Summarise key results with reference to study objectives	P 13 - 16
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	P 16
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	P 14 -16
Generalisability	21	Discuss the generalisability (external validity) of the study results	P 16
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	P 17

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

BMJ Open

The prevalence of metabolic syndrome and diabetes mellitus in Sami and Norwegian populations. The SAMINOR- a cross sectional study.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2015-009474.R1
Article Type:	Research
Date Submitted by the Author:	20-Oct-2015
Complete List of Authors:	Broderstad, Ann Ragnhild; Uit the Arctic University of Norway, Centre for Sami Health Research, Faculty of Health Melhus, Marita; Uit the Arctic University of Norway, Centre of Sami Health research, Faculty of Health
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Diabetes and endocrinology, Epidemiology, Public health, Nutrition and metabolism
Keywords:	Hypertension < CARDIOLOGY, General diabetes < DIABETES & ENDOCRINOLOGY, General endocrinology < DIABETES & ENDOCRINOLOGY, Lipid disorders < DIABETES & ENDOCRINOLOGY, EPIDEMIOLOGY

SCHOLARONE™
Manuscripts

Original Article**The prevalence of metabolic syndrome and diabetes mellitus in Sami and Norwegian populations. The SAMINOR-a cross sectional study.****Authors:**Ann Ragnhild Broderstad ^{1,2}Marita Melhus ¹

1. Centre for Sami Health Research, University of Tromsø The Arctic University of Norway

2. Medical Department, University Hospital of North Norway, Harstad

Contact details:

Ann Ragnhild Broderstad

Centre for Sami Health Research

University of Tromsø The Arctic University of Norway

N-9037 Tromsø

Norway

e-mail: Ann.Ragnhild.Broderstad@uit.no

Telephone +47 776 44000 / +47 78 46 89 00 Fax +47 78 46 89 10/ +47 76985021

Running head; Metabolic syndrome and diabetes among Sami and non-Sami

Keywords Metabolic, obesity, Sami, SAMINOR, diabetes

Words 2964

Tables 3

Figures 2

Abstract

Objectives

Metabolic syndrome (MetS) is recognized as a reliable long-term predictor of adverse health outcomes known. Elevated prevalence rates of MetS and chronic lifestyle diseases have been documented in different indigenous groups. We wanted to evaluate the prevalence of MetS and diabetes mellitus in relation to ethnicity in Northern Norway. In addition, we discussed different cut-off values for waist circumference (WC) and what impact this has on the prevalence of MetS.

Material and methods

SAMINOR is a population based study of health and living conditions in areas home to both Sami and non-Sami populations. The survey was carried through in 2003 – 2004. All eligible residents in specific age groups were invited. In total, 16,538 males and females aged 36-79 participated and gave informed consent for medical research.

Results

This study involved a total of 7,822 female and 7,290 male participants. Sami affiliation was reported by 5,141 participants (34 per cent). The prevalence of MetS was high in both ethnic groups independent of which WC cut off values used. The two different WC cut-off values greatly influenced the measured prevalence of MetS. Diabetes prevalence was significant higher among Sami men and women (5,2 per cent and 5,0 per cent) compared to the non-Sami participants (4,5 per cent and 4,2 per cent).

Conclusions

In this study we demonstrated a high share of negative metabolic components. The prevalence of diabetes was higher among the Sami participants than among the non-Sami, in both genders, even though the presence of MetS among men were higher among the non-Sami. These metabolic components have important health implications. Therefore, determining

1
2
3 preventive initiatives is important in the primary and specialist health care system. These
4
5 initiatives must be made culture and linguistic specific, in order to reduce differences and
6
7 improve health status in the whole population.
8
9

10 11 12 13 14 15 **Strengths and limitations of this study** 16

- 17 • The SAMINOR study is the first survey to report on the prevalence of diabetes and
18 MetS in a large geographic area of North Norway including both the indigenous and
19 the non-indigenous population.
20
21
- 22 • The large sample size allowed for detailed analysis of diabetes and MetS in Sami and
23 non-Sami populations of rural North Norway.
24
25
- 26 • The survey has a relatively high response rate.
27
28
- 29 • Categorizing people based on ethnicity is a contentious practice. Different studies use
30 different criteria of ethnicity, which makes it difficult to compare results.
31
32
- 33 • Cross-sectional data cannot assess the effect of lifestyle on the incidence of MetS, and
34 longitudinal cohort studies are therefore needed
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **The prevalence of metabolic syndrome and diabetes mellitus in Sami and Norwegian**
4 **populations. The SAMINOR study-a cross sectional study.**
5
6
7

8 **Introduction**
9

10 Chronic disease has become a global problem and a burden on health care services, reaching
11 epidemic proportions. In Norway, as well as internationally, the great majority of patients in
12 health care systems are living with chronic disease.[1-2] Cardiovascular disease (CVD), type
13 2 diabetes mellitus (T2DM), cancer and chronic obstructive pulmonary disease (COPD) are the
14 most common causes of hospitalization and premature death.[3] Unfavorable health factors
15 such as obesity, insulin resistance, dyslipidemia and hypertension are known to elevate risks
16 of developing CVD and T2DM. Metabolic syndrome (MetS) indicates a cluster of these risk
17 factors. [4-5] MetS is generally recognized as a reliable long-term predictor of adverse health
18 outcomes.[6] Further, MetS has been recognized as a growing, global public health problem.
19 .[7] In addition, several studies demonstrate MetS to be associated with elevated cancer
20 risk.[8-9]
21
22
23
24
25
26
27
28
29
30
31
32
33
34

35 Information on the prevalence of chronic disease in various ethnicities of North Norway
36 remains sparse. The Sami, Kven and Norwegian ethnic groups are recognized as having
37 inhabited the region in centuries; the Norwegian government acknowledges the Sami people
38 as the indigenous people of Norway. The Norwegian health authorities have little systematic
39 knowledge about health status and living conditions among the Sami. National health -and
40 medical registers contribute to comprehensive information and knowledge about health-
41 related lifestyle and disease prevalence. However, information about ethnic background is not
42 permitted by law, in these registers nor in patient's medical records. Therefore, no reliable or
43 updated demographic records on the Sami exists that can be used for health research purposes.
44 Several epidemiological studies have documented elevated prevalence rates for chronic
45 lifestyle diseases in a number of different minority groups.[5, 10 -11] Although such disorders
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 have emerged quite recently in indigenous populations — mainly due to changes in lifestyle
4 and diet — they are, however, prevalent in several indigenous populations.[12-13]

5
6
7 Publications from the SAMINOR study of North Norway demonstrate that the prevalence of
8 obesity was high in the survey population, especially among Sami women.[14-15]

9
10
11 In order to evaluate the health of indigenous and non-indigenous populations of Norway
12 (inhabiting the same geographic area) it was necessary to conduct an epidemiological survey.
13
14 The present study aims to evaluate the prevalence of MetS and diabetes mellitus in Sami and
15 non-Sami populations residing in selected areas of North Norway. In addition, we will discuss
16 different cut-off values for waist circumference (WC) and what impact this has on the
17 prevalence of MetS.
18
19
20
21
22
23
24

25 **Methods**

26 *The SAMINOR study*

27
28
29 The cross-sectional data is derived from the SAMINOR study of 2003–2004 (SAMINOR 1).
30
31 The SAMINOR study was conducted by The Centre for Sami Health Research, Department
32 of Community Medicine, UiT The Arctic University of Norway, in collaboration with the
33 National Screening Program for Cardiovascular Diseases. The survey is described in detail
34 elsewhere.[16]
35
36
37
38
39

40 *The study sample*

41
42 All eligible residents aged 30 and 36–79 years registered in the Central Population Register
43 in 24 selected municipalities were invited regardless of ethnic background (n=27,987). Due to
44 a low response rate among those aged 30 years, our analyses were restricted to the age
45 interval 36 –79 years (n=27,151). In total, 16,538 males and females aged 36 –79
46 participated and gave informed consent for medical research. The response rate was 61 per
47 cent. Data was obtained from physical tests and blood samples. Information on ethnicity, and
48 the different diagnostic tools for MetS, were available for 15,112 participants.
49
50
51
52
53
54
55
56
57
58
59
60

Questionnaire design

An invitation was mailed several weeks before the survey arrived the municipality. The invitation contained information about the time and place, together with a five-page questionnaire. Those who agreed to attend the screening returned the questionnaire to the Norwegian Institute of Public health. These participants received later an invitation to the clinical examination. After the consultation the participants were asked to complete a new questionnaire. Information regarding ethnicity, disease and lifestyle were collected using these two self-administrated questionnaires. The questionnaires were translated into the three main Sami languages, Northern, Lule and South Sami languages. However, as only 1.6% of the participants chose to use the Sami version of the questionnaire, any language problems are probably of little importance in this study. Ethnicity was measured using the following questions: "*What language(s) do/did you, your parents and your grandparents use at home?*" The questions were to be answered separately for each relative. The available responses were: "Norwegian", "Sami", "Kven" and "Other". Multiple answers were allowed. Providing the same response options we also asked: "*What is your, your father's and your mother's ethnic background?*" The respondents also reported whether they considered themselves to be Norwegian, Sami, Kven or other (self-perceived ethnicity). We refer to Lund et al (16) for full description of the ethnicity and language questions. Based on these variables we generated two categories of ethnicity: "Sami" and "Non-Sami". Participants reporting at least one Sami identity mark (Sami language spoken by the respondent or at least one parent or grandparent, or Sami ethnic background or self-perceived Sami ethnicity) were placed in the category "Sami". The "Non-Sami" comprised the remainder of the participants.

The study was accredited by the Regional Board of Research Ethics in Northern Norway, and by the Board's Sami Consultant. The survey is in accordance with the Helsinki Declaration of

1
2
3 1975. The National Data Protection Authority (*Datatilsynet*) approved the use of personal
4 information and the study are registered with the number 2002/1525-2.
5
6

7 *Screening*

8
9 Due to the large size of the study sample participants were examined at different times of day.
10
11 This meant that it was not possible to ask participants to be fasting prior to arrival. Non-
12
13 fasting blood samples were obtained at the research station. Blood samples were drawn by
14
15 venopuncture at normal venous pressure in sitting position. Serum was separated at the station
16
17 within 1.5 hours. Serum was sent by overnight mail to laboratories in Oslo and Tromsø. The
18
19 laboratory analyses are described in detail elsewhere.[17]
20
21

22
23 Body mass index (BMI) was based on measurements of weight and height, and expressed as
24
25 body weight in kilograms/(body height in meters)². BMI categories were defined according to
26
27 guidelines from The World Health Organization (WHO); 'underweight' corresponding to a
28
29 BMI < 18.5 kg/m², 'standard weight' in the range 18.5–24.9 kg/m², 'overweight' in the range 25
30
31 – 29.9 kg/m² and 'obese' ≥ 30 kg/m². [18]
32
33

34
35 Waist circumference (WC), which is used to identify abdominal obesity, was measured (to the
36
37 nearest centimeter) at the umbilicus with the participant standing erect. Two different WC
38
39 cut-off values were applied to define abdominal obesity to enable the comparison of how the
40
41 corresponding values influenced the subsequently calculated prevalence of MetS. The US
42
43 National Institute of Health (NIH) Clinical Practice Guidelines defines central/abdominal
44
45 obesity as WC ≥ 102 cm in males and WC ≥ 88 cm in females. [19] In addition, abnormal WC
46
47 for European males are ≥ 94 cm and for females ≥ 80 cm. These figures are based on cross-
48
49 sectional data from Europeans and were included in the analyses. [18,20]
50
51

52 Trained personnel measured blood pressure, using Dinamap –R. automatic device.

53
54 Measurements were initiated after subjects had been seated for two minutes with their arms
55
56
57
58
59
60

1
2
3 resting on a table. Blood pressure was measured three times, with one- minute intervals. The
4
5 mean value of the second and third reading was used in the analysis.
6

7 8 *Diabetes mellitus*

9
10 Because all blood samples in the SAMINOR study were non-fasting, we used random plasma
11
12 glucose ≥ 11.1 mmol/L, in addition to self-reported diabetes and information about anti-
13
14 diabetic medication from a questionnaire to define diabetes mellitus. The question about
15
16 diabetes mellitus was; “Do you have or have you had diabetes?” The available responses
17
18 were “Yes” or “No”. Missing values were classified as “No”. In the absence of oral glucose
19
20 tolerance tests we used random plasma glucose ≥ 11.1 mmol/l as a substitute for elevated oral
21
22 glucose tolerance test.
23

24 25 *Metabolic syndrome*

26
27 Several attempts have been made at developing diagnostic criteria for the definition of MetS.
28
29 [21-23] In 2004, the International Diabetes Federation (IDF), the WHO and the National
30
31 Cholesterol Education Program Third Adult Treatment Panel (ATP III) produced a consensus
32
33 statement on the definition of MetS.[24] The latter definition requires central obesity and cut-
34
35 off points to be specified according to gender and ethnicity. Central obesity is most commonly
36
37 measured by WC; cut-off values are based on cross-sectional studies conducted in Europe,
38
39 The United States and Asia.[18-20, 25] The diagnostic tools are intended for clinical and
40
41 research purposes. The definition of MetS used in this article adheres to the IDF MetS
42
43 worldwide definition,[24]: Central obesity plus any two of four additional factors; Elevated
44
45 triglyceride level > 1.7 mmol/l, reduced HDL-cholesterol < 1.03 mmol/l in males and < 1.29
46
47 mmol/l in females, elevated blood pressure (systolic BP ≥ 130 or diastolic BP ≥ 85 mmHg)
48
49 and elevated fasting plasma glucose ≥ 11.1 mmol/l or previously diagnosed type 2 diabetes.
50
51

52 53 *Statistical analyses*

All analyses were stratified by gender. Sample characteristics were presented separately by gender and ethnicity as mean values for continuous variables with corresponding 95 per cent confidence intervals. Analyses of variance (ANOVA) were used for tests of ethnic differences (Table 1). Differences according to diabetes mellitus and Mets prevalence were tested by Chi-square tests (Tables 2 and 3). MetS prevalence was also stratified by age (Table 3). Logistic regression analyses were used to test for age influence on MetS with age as a continuous variable (Table 3).

We used the SAS statistical software package, version 9.3 (SAS Institute Inc., Cary, NC, USA).

Results

The current analysis involved a total of 7,822 female and 7,290 male participants. Sami affiliation was reported by 5,141 participants (34 per cent). Table 1 shows gender-specific and ethnicity-specific characteristics at enrolment in the study.

Table 1 Sample characteristics by gender and ethnic group. (N= 15 112)

Men	Sami (N=2559)	Non-Sami (N=4731)	p-value ²
	Mean (95 % CI) ¹	Mean (95 % CI) ¹	
Age (yr)	55.0 (54.8-55.1)	54.8 (54.7-54.9)	0.584
Height (cm)	170.0 (170.0-170.2)	175.7 (175.6 – 175.8)	<0.0001
Weight (kg)	80.6 (80.4 – 80.7)	85.1 (85.0 – 85.3)	<0.0001
BMI (kg/m ²)	27.8 (27.7-27.9)	27.5 (27.5 – 27.6)	0.009
WC (cm)	93.2 (93.0 – 93.3)	95.0 (94.9 – 95.2)	<0.0001
Non-fasting glu (mmol/L)	5.8 (5.8- 5.8)	5.8 (5.7 – 5.8)	0.313
HDL- chol (mmol/l)	1.27 (1.26 – 1.28)	1.25 (1.25 – 1.26)	0.115
LDL- chol (mmol/L)	3.87 (3.86 – 3.89)	3.80 (3.79 – 3.81)	0.004
Cholesterol (mmol/l)	5.98 (5.96- 5.99)	5.90 (5.90 – 5.90)	0.001
Triglycerids (mmol/l)	1.86 (1.85 – 1.88)	1.86 (1.85 – 1.88)	0.970
Systolic BT (mmHg)	135 (135 – 135)	134 (134 -134)	0.168
Diastolic BT (mmHg)	78 (78 -78)	78 (78 – 78)	0.182
Women	Sami (N=2581)	Non-Sami (N=5241)	p-value
	Mean (95 % CI)¹	Mean (95 % CI)¹	
Age (yr)	54.2 (54.1 – 54.4)	54.5 (54.4 – 54.6)	0.277
Height (cm)	157.3 (157.2 – 157.4)	162.6 (162.6 – 162.7)	<0.0001

Weight (kg)	69.7 (69.6 – 69.9)	72.1 (71.9 – 72.2)	<0.0001
BMI (kg/m ²)	28.2 (28.1 – 28.3)	27.3 (27.2 – 27.3)	<0.0001
WC (cm)	86.0 (85.9 – 86.2)	85.5 (85.4 – 85.6)	0.053
Non-fasting glu (mmol/L)	5.66 (5.63 – 5.68)	5.57 (5.55 – 5.58)	0.018
HDL-cholesterol (mmol/l)	1.45 (1.44 – 1.45)	1.49 (1.49 – 1.50)	<0.0001
LDL-cholesterol (mmol/L)	3.82 (3.81 – 3.83)	3.81 (3.80 – 3.82)	0.707

Sami
(N=2559)

Non-Sami
(N=4731)

Cholesterol (mmol/l)	5.98 (5.96 – 5.99)	5.99 (5.98 – 6.00)	0.617
Triglycerids (mmol/l)	1.54 (1.56 – 1.59)	1.53 (1.52 – 1.54)	0.044
Systolic BT (mmHg)	130 (129 – 130)	130 (130 – 131)	0.125
Diastolic BT (mmHg)	72 (72 – 72)	73 (73 – 73)	0.008

¹ 95% confidence interval

² test of differences, ANOVA, for between Sami versus non-Sami

The mean BMI was greater in Sami males, whereas the mean WC was greater in non-Sami males. Sami females, however, showed significantly greater values for mean BMI, WC and lipids.

Table 2 shows the prevalence of diabetes in Sami and non-Sami participants.

Table 2. Prevalence of diabetes mellitus in the SAMINOR study (N=15112)

Men	<i>n</i> (%)	<i>n</i> (%)	p-value ¹
Diabetes prevalence	132 (5.2)	212 (4.5)	0.05
Insulin treatment	13 (0.5)	31 (0.7)	
Tablet treatment	45 (1.8)	87 (1.8)	
Insulin and tablet treatment	25 (1.0)	21 (0.4)	
Non- treatment	49 (1.9)	73 (1.5)	
	Sami (N=2581)	Non-Sami (N=5241)	
Women	<i>n</i> (%)	<i>n</i> (%)	p-value ¹
Diabetes prevalence	129 (5.0)	220 (4.2)	0.026
Insulin treatment	13 (0.5)	29 (0.6)	
Tablet treatment	61 (2.4)	71 (1.6)	
Insulin and tablet treatment	20 (0.8)	38 (0.7)	
Non- treatment	35 (1.4)	82 (1.6)	

¹ Chi-square test for differences in diabetes prevalence among Sami versus non-Sami

Diabetes was significant more frequent among the Sami participants than the non-Sami in both gender. Ethnicity appeared therefore to affect diabetes prevalence.

The prevalence of the various diagnostic tools for MetS is presented in Figures 1 (males) and 2 (females).

1
2
3
4
5 -----Figure 1 -----
6
7
8

9
10 -----Figure 2 -----
11
12

13
14
15
16 The most prevalent risk marker for MetS (aside from central obesity) was the presence of
17 elevated systolic blood pressure and high triglyceride levels independent of gender and
18 ethnicity.
19
20
21

22
23 Table 3 presents the prevalence of MetS according to WC cut-off points based on European
24 and NIH values.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

56 **Table 3.** Prevalence of MetS among Sami and non-Sami, by age groups and gender. N=
57 15112 participants
58
59
60

12

	European cut off of WC		p-value ¹	NIH cut off of WC		p-value ¹
	Sami (N=650) n (%)	Non-Sami (N=917) n (%)		Sami (N=315) n (%)	Non-Sami (N=728) n (%)	
Men						
36-49 yr	194 (22.3)	429 (26.0)	0.038	89 (10.2)	203 (12.3)	0.118
50-59 yr	229 (27.2)	440 (29.7)	0.202	115 (13.7)	238 (16.1)	0.121
60-79 yr	227 (26.9)	489 (30.6)	0.055	111 (13.1)	287 (18.0)	0.002
p-value ²	0.029	<0.0001		0.05	<0.0001	
	Sami (N=790) n (%)	Non-Sami (N=1521) n (%)		Sami (N=588) n (%)	Non-Sami (N=1091) n (%)	
Women						
36-49 yr	232 (24.4)	369 (19.1)	0.006	161 (16.2)	263 (13.6)	0.056
50-59 yr	248 (31.5)	455 (29.4)	0.291	177 (22.5)	309 (20.0)	0.155
60-79 yr	310 (38.7)	697 (39.6)	0.641	250 (31.2)	519 (29.5)	0.393
p-value ²	0.004	<0.0001		<0.0001	<0.0001	

¹ Chi-square tests for differences in MetS prevalence of Sami versus non-Sami

² Age effect tested by logistic regression with age as a continuous variable

In each age bracket the results are stratified according to ethnicity (Sami and non-Sami).

Based on the European WC cut-off points, prevalence of MetS was higher in non-Sami participants in the age bracket 36-49 years. However, when applying the NIH WC cut-off point, a significantly lower prevalence was found for Sami males in the top age group.

1
2
3 Non-Sami males showed a higher overall prevalence of MetS (in comparison to Sami males)
4
5 for both WC cut-off values. In females ethnicity was not significant overall; however when
6
7 stratified by age, a significantly higher prevalence of MetS in the younger Sami females (in
8
9 comparison to non-Sami females) was found — when applying the European WC cut-off
10
11 value. The prevalence of MetS increased with age regardless of gender and ethnicity. The
12
13 proportion of women with all four risk markers was almost twice as large within the Sami
14
15 population (in comparison to non-Sami females) for both WC cut-off values (not shown). For
16
17 males, ethnicity appeared not to affect the number of risk markers found.
18
19
20
21
22

23 Discussion

24
25 The prevalence of MetS was high in both ethnic groups. Diabetes prevalence was significant
26
27 higher among both Sami men and women compared to the non-Sami participants. The two
28
29 different WC cut-off values greatly influenced the measured prevalence of MetS. The present
30
31 study demonstrates that ethnicity is a significant factor for MetS in participants belonging to
32
33 the lowest age bracket.
34
35

36 The two different WC cut-off values greatly influenced the measured prevalence of MetS.

37
38 The present study demonstrates that ethnicity is a significant factor for MetS in participants
39
40 belonging to the lowest age bracket. In the case of males aged between 36 and 49, MetS is
41
42 less prevalent in the Sami population (in comparison to non-Sami). For females in the same
43
44 age bracket, however, MetS is more prevalent in the Sami population. When the NIH cutoffs
45
46 were used, we found that — in the highest age bracket — the non-Sami males showed
47
48 significantly higher prevalence of MetS in comparison to Sami males. The prevalence of
49
50 MetS increased significantly by age in both ethnic groups, regardless of which WC cut-off
51
52 values were used.
53
54
55
56
57
58
59
60

1
2
3 In general, overweight and obesity are common among the participants in the SAMINOR
4 study. From earlier publications based on the SAMINOR study, central obesity has been
5 shown to be more common in Sami females.[15,26] General obesity in Sami females has also
6 been discussed by Njølstad et al (1998).[27] However, obesity rates were high in non-Sami
7 females as well.[14] For males, central obesity occurred more frequently in the non-Sami
8 population relative to the Sami population.[14-15]

9
10 MetS has several different definitions, making it difficult to directly compare and contrast
11 prevalence found in different surveys. WC is the most significant measurement of both central
12 obesity and fat distribution, according to The International Diabetes Federation (IDF).[28]

13
14 The group that produced the consensus statement on the definition of MetS in 2004
15 recommended that gender and ethnicity should be the basis for classification of cut-off points.
16 [24] The existing values are based on cross-sectional population survey data from the
17 respective countries. How to define the WC cut-off point in the various indigenous
18 populations has not yet been established; however, an immediate response would be to
19 perform cross-sectional population surveys within indigenous societies. In our study two
20 different cut-off points were used in order to facilitate comparison. The European cut-off
21 values doubled the prevalence of MetS in males and increased prevalence by more than 40 per
22 cent in females (compared to values found when applying NIH WC cut-off values). This was
23 the case in both ethnic groups. But the question of what the WC values should be in terms of
24 optimal prediction of prospective disease in the SAMINOR sample remains unanswered. A
25 follow-up study could provide better answers to questions regarding disease development.
26 Irrespective of cut-off values, elevated blood pressure was the most frequent MetS component
27 present in obese participants. These findings were also demonstrated in a collaborative
28 analysis of ten large cohort studies in Europe.[29] In the ten studies included, obesity
29 coincided with hypertension in up to 85 per cent of cases.

1
2
3 The presence of MetS, as well as its individual components, however, shows considerable
4 variance between populations. Several studies of MetS have been performed in circumpolar
5 areas, such as in indigenous peoples of Alaska, Canada and Greenland.[30-32] American
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The presence of MetS, as well as its individual components, however, shows considerable variance between populations. Several studies of MetS have been performed in circumpolar areas, such as in indigenous peoples of Alaska, Canada and Greenland.[30-32] American Indians and Aboriginal Canadians represent populations in which MetS, obesity and T2DM are becoming more prevalent. [13,30] MetS is also frequently occurring in Greenland's Inuit population.[32] A health survey in Greenland showed that central adiposity and obesity were more prevalent in the Inuit population when compared to the corresponding Danish population, but was not associated with the same degree of metabolic disturbance as in the general Danish population.[33] Yet it is debatable which factors in the cluster of MetS are the most significant in the development of chronic lifestyle diseases.

There is a significant relation between T2DM and MetS; the syndrome itself is not a disease, but consists of a cluster of factors that increase the risk for developing diseases. Thus we prefer to include diabetes in this article to demonstrate the link between the health indicator MetS and diabetes mellitus.[24] In the SAMINOR study diabetes mellitus was identified using a questionnaire, in addition to measured random plasma glucose ≥ 11.1 mmol/L in participants whom did not report diabetes mellitus. As the study had a large number of participants, up to 140 per day, conducting two-hour plasma glucose tolerance tests was considered infeasible. The portable HbA1c instruments available in 2003-2004 were inadequate for conducting HbA1C measurements at rural research stations. In addition, the survey was performed in provincial areas with long distances to the medical laboratory. Our analyses do not differentiate between type 1 and 2 diabetes mellitus due to insufficient information provided by the questionnaire. However, eight of ten diabetes cases in Norway are T2DM.[34] Also, globally, around 80 per cent of diabetes cases are T2DM,[35-37] giving a prevalence rate of 8.3 per cent. This figure is expected to increase due to lifestyle changes. [36] Diabetes prevalence in our study was between four and five percent, which is a lower

1
2
3 rate than the prevalence rate found in the urban population residing in 2007—2008 in the city
4 of Tromsø (8.5%) [38]. This study encompassed participants aged between 30 and 87, with a
5 mean age of 61. However, in the Tromsø study, fasting plasma glucose, two-hour plasma
6 glucose and HbA1c was measured. It is therefore likely that the present study underreports the
7 diabetes prevalence maybe as much as up to 50 percent.
8
9

10 11 12 13 *Strengths*

14
15 Our study is the first survey to report on the prevalence of diabetes and MetS in a large
16 geographic area of North Norway including both the indigenous and the non-indigenous
17 population. The large sample size allowed for detailed analysis of diabetes and MetS in Sami
18 and non-Sami populations of rural North Norway; it also reduces the influence of random
19 errors, which cannot fully be controlled for. The survey had a relatively high response rate.
20 Unquestionably, one of the strengths of the study was that clinical data — such as central
21 obesity (upon which MetS relies) — were collected by direct measurement and conducted by
22 trained personnel, providing reliable estimates of obesity prevalence in the participating
23 cohort.
24
25
26
27
28
29
30
31
32
33
34

35 36 37 *Limitations*

38
39 The cross-sectional study design is suitable for the examination of associations in order to
40 generate hypotheses that may be explored in longitudinal studies. Conversely, however, the
41 design prevents the establishment of causality. Due to the nature of the design, people with
42 severe disease may be missed because they are diseased at home, in long-term hospitalization
43 or having died in the time since the sample list was prepared (i.e., selection bias). The
44 SAMINOR study has used questionnaires to survey self-reported diseases. This approach
45 cannot detect people with undiagnosed symptoms and is limited by recall bias. In
46 Norway, it is estimated between 90 000 to 120 000 people with diabetes and nearly as many
47 have undiagnosed disease. [39]
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Categorizing people based on ethnicity is a contentious practice. Different studies use
4 different criteria of ethnic categorization, which makes it difficult to compare results. Our
5 definition of the Sami group is rather weak. This may have influenced our results. Since there
6 are no national records with information on ethnic background, it is impossible to know if the
7 response rate among Sami and non-Sami are different. We are therefore unable to assess
8 whether differences in participation have influenced the observed disease burden.
9

10
11 In summary, cross-sectional studies may be used in the measurement of the burden of disease
12 in a population. However, cross-sectional data cannot assess the effect of lifestyle on the
13 incidence of MetS, and longitudinal cohort studies are therefore needed.
14

15 16 17 18 19 20 21 22 23 **Conclusion**

24 Without question, the prevalence rates for several negative health factors were high in the
25 Sami and non-Sami population. Overweight and obesity were common, especially in the case
26 of Sami females. The prevalence of diabetes was higher among the Sami participants than the
27 non-Sami in both genders, even though the prevalence of MetS among men were higher among
28 the non-Sami men. However, the prevalence of MetS were in general high among participants
29 in the SAMINOR study, with the highest prevalence for the European cut off values. The
30 syndrome has important health implication but a cross sectional study cannot be used to
31 validate the best ethnic specific values for WC used in the definition of MetS and more data
32 on this issue must be obtained. In addition, determining preventive initiatives is important in
33 the primary and specialist health care system. These initiatives must be made culture and
34 linguistic specific, in order to reduce differences and improve health status in the whole
35 population.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 52 53 **Acknowledgements**

54 We are indebted to the participants of the SAMINOR study, without whom our research
55 would be impossible. We would also like to thank the staff at the Department of Clinical
56
57
58
59
60

1
2
3 Chemistry, University Hospital of North Norway, for technical assistance and careful
4 evaluation of blood samples.

5
6 Funding for this project was provided by the Norwegian Ministry of Health and Care
7 Services.
8
9

10 11 **Conflict of Interest:**

12 The authors declare that they have no conflict of interest.
13
14

15 16 **Data sharing**

17 Extra data is available by emailing ann.ragnhild.broderstad@uit.no
18
19

20 21 **Summary Box**

22 *What is already known on this subject?*

23
24 In Northern Norway the burden of obesity are especially high among female. Highest
25 prevalence has been demonstrated among the Sami women. In this study we therefore
26 examined several other risk factors for developing lifestyle diseases.
27
28
29

30 *What this study adds?*

31
32 This study showed a high prevalence of the metabolic syndrome among the population in
33 north, independent of ethnic belonging. The burden of metabolic risk factors was highest
34 among women, especially Sami women. Self-reported diabetes was between four and five
35 percent which are slightly higher than the national prevalence rate. In the future, obesity and
36 other metabolic risk factors will contribute to increase burden of lifestyle diseases among the
37 Sami population. Two issues are therefore important to emphasize. Firstly, implement
38 preventive interventions in the multicultural communities, as well as highlight research
39 information to inhabitants and local and central authorities. Secondly, follow the health
40 situation in each community with longitudinal studies to evaluate the effect of preventive
41 efforts.
42
43
44
45
46
47
48
49

50 51 **Contributorship statement.**

52 The idea behind the study was conceived by Ann R Broderstad. Both authors participated in
53 the study concept and design. Ann R Broderstad drafted the manuscript. Both authors did the
54
55
56
57
58
59

1
2
3 analyses of the tables and figures. Both authors reviewed and approved the final version of the
4
5 manuscript.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 **References**

- 50
51 1. Banatvala N, Donaldson L. Chronic diseases in developing countries. *Lancet* 2007;
52 370(9605): 2076-8.
53
54
55
56
57
58
59
60

2. Dale AC, Nilsen TI, Vatten L, Midthjell K, Wiseth R. Diabetes mellitus and risk of fatal ischaemic heart disease by gender: 18 years follow-up of 74,914 individuals in the HUNT 1 Study. *European heart journal* 2007; 28(23): 2924-9.
3. Parajuli R, Bjerkaas E, Tverdal A, et al. The increased risk of colon cancer due to cigarette smoking may be greater in women than men. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology* 2013; 22(5): 862-71.
4. Grundy SM, Brewer HB, Jr., Cleeman JI, et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. *Circulation* 2004; 109(3): 433-8.
5. Simmons RK, Alberti KG, Gale EA, et al. The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. *Diabetologia* 2010; 53(4): 600-5.
6. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. *Diabetes care* 2005; 28(7): 1769-78.
7. Goldstein MR, Mascitelli L, Pezzetta F. On treating metabolic syndrome: emphasise lifestyle change. *The Lancet Oncology* 2010; 11(5): 415.
8. Ishino K, Mutoh M, Totsuka Y, Nakagama H. Metabolic syndrome: A novel high-risk state for colorectal cancer. *Cancer letters* 2012.
9. Russo A, Autelitano M, Bisanti L. Metabolic syndrome and cancer risk. *European journal of cancer* 2008; 44(2): 293-7.
10. Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. *Endocrinology and metabolism clinics of North America* 2004; 33(2): 351-75, table of contents.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
11. Boyer BB, Mohatt GV, Plaetke R, et al. Metabolic syndrome in Yup'ik Eskimos: the Center for Alaska Native Health Research (CANHR) Study. *Obesity* 2007; 15(11): 2535-40.
 12. Liu J, Young TK, Zinman B, Harris SB, Connelly PW, Hanley AJ. Lifestyle variables, non-traditional cardiovascular risk factors, and the metabolic syndrome in an Aboriginal Canadian population. *Obesity* 2006; 14(3): 500-8.
 13. Schumacher C, Ferucci ED, Lanier AP, et al. Metabolic syndrome: prevalence among American Indian and Alaska native people living in the southwestern United States and in Alaska. *Metabolic syndrome and related disorders* 2008; 6(4): 267-73.
 14. Nystad T, Melhus M, Brustad M, Lund E. Ethnic differences in the prevalence of general and central obesity among the Sami and Norwegian populations: the SAMINOR study. *Scandinavian journal of public health* 2010; 38(1): 17-24.
 15. Broderstad AR, Melhus M, Lund E. Iron status in a multiethnic population (age 36-80 yr) in northern Norway: the SAMINOR study. *European journal of haematology* 2007; 79(5): 447-54.
 16. Lund E, Melhus M, Hansen KL, et al. Population based study of health and living conditions in areas with both Sami and Norwegian populations--the SAMINOR study. *International journal of circumpolar health* 2007; 66(2): 113-28.
 17. Nystod T, Utsi E, Selmer R, Brox J, Melhus M, Lund E. Distribution of apoB/apoA-1 ratio and blood lipids in Sami, Kven and Norwegian populations: the SAMINOR study. *Int J Circumpolar Health* 2008; 67(1): 67-81.
 18. WHO technical Report Series 894. Obesity: Preventing and Managing the Global Epidemic. World Health Organization : Geneva, Switzerland, 2000.; 1997. Report by the Secretariat http://apps.who.int/gb/ebwha/pdf_files/EB130/B130_9-en.pdf

- 1
2
3 19. Janssen I, Peter T, Katzmarzyk PT, Ross R. Body Mass Index, Waist Circumference,
4 and Health RiskEvidence in Support of Current National Institutes of Health Guidelines *Arch*
5
6
7 *Intern Med.* 2002;162(18):2074-2079.
8
9
10 20. Lean ME, Han TS, Morrison CE. Waist circumference as a measure for indicating
11 need for weight management. *Bmj* 1995; 311(6998): 158-61.
12
13 21. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus
14 and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional
15 report of a WHO consultation. *Diabetic medicine : a journal of the British Diabetic*
16
17 *Association* 1998; 15(7): 539-53.
18
19 22. Balkau B, Charles MA. Comment on the provisional report from the WHO
20 consultation. European Group for the Study of Insulin Resistance (EGIR). *Diabetic medicine :*
21
22 *a journal of the British Diabetic Association* 1999; 16(5): 442-3.
23
24 23. Cleeman JI. Executive summary of the third report of the National Cholesterol
25 Education Program (NCEP) expert panel on detection, evaluation, and treatment of high
26 blood cholesterol in adults (adult treatment panel III). *Journal of the American Medical*
27
28 *Association* 2001; 285(19): 2486 -97.
29
30 24. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome--a new world-wide definition. A
31 Consensus Statement from the International Diabetes Federation. *Diabetic medicine : a*
32
33 *journal of the British Diabetic Association* 2006; 23(5): 469-80.
34
35 25. Lin WY, Lee LT, Chen CY, et al. Optimal cut-off values for obesity: using simple
36 anthropometric indices to predict cardiovascular risk factors in Taiwan. *International journal*
37
38 *of obesity and related metabolic disorders : journal of the International Association for the*
39
40 *Study of Obesity* 2002; 26(9): 1232-8.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 26. Nystad T, Melhus M, Brustad M, Lund E. Ethnic differences in the prevalence of
4 general and central obesity among the Sami and Norwegian populations: the SAMINOR
5 study. *Scand J Public Health*; 38(1): 17-24.
6
7
8
9
10 27. Njolstad I, Arnesen E, Lund-Larsen PG. Cardiovascular diseases and diabetes mellitus
11 in different ethnic groups: the Finnmark study. *Epidemiology* 1998; 9(5): 550-6.
12
13
14 28. Carr DB, Utzschneider KM, Hull RL, et al. Intra-abdominal fat is a major determinant
15 of the National Cholesterol Education Program Adult Treatment Panel III criteria for the
16 metabolic syndrome. *Diabetes* 2004; 53(8): 2087-94.
17
18
19
20 29. van Vliet-Ostaptchouk JV, Nuotio ML, Slagter SN, et al. The prevalence of metabolic
21 syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large
22 cohort studies. *BMC endocrine disorders* 2014; 14: 9.
23
24
25
26
27 30. Ley SH, Harris SB, Mamakeesick M, et al. Metabolic syndrome and its components as
28 predictors of incident type 2 diabetes mellitus in an Aboriginal community. *Cmaj* 2009;
29 180(6): 617-24.
30
31
32
33 31. Russell M, de Simone G, Resnick HE, Howard BV. The metabolic syndrome in
34 American Indians: the strong heart study. *J Cardiometab Syndr* 2007; 2(4): 283-7.
35
36
37
38 32. Jorgensen ME, Bjerregaard P, Gyntelberg F, Borch-Johnsen K. Prevalence of the
39 metabolic syndrome among the Inuit in Greenland. A comparison between two proposed
40 definitions. *Diabet Med* 2004; 21(11): 1237-42.
41
42
43
44 33. Jorgensen ME. Obesity and metabolic correlates among the Inuit and a general Danish
45 population. *Int J Circumpolar Health* 2004; 63 Suppl 2: 77-9.
46
47
48
49 34. Folkehelseinstituttet. Forekomst av diabetes - faktaark med helsestatistikk.
50 <http://www.fhi.no/artikler/?id=70814>
51
52
53
54 Folkehelseinstituttet; 2015.
55
56
57
58
59
60

- 1
2
3 35. Velho G, Froguel P, Mann J, Toeller M. Type 2 Diabetes. In: Ekoe J, Zimmet P,
4 Williams R, eds. The Epidemiology of Diabetes mellitus. Chichester, England: John Wiley &
5 Sons Ltd; 2001: 133-53.
6
7
8
9
10 36. Federation ID. IDF Diabetes Atlas. 6th edition [internet]. 2013.
11 <http://idf.org/diabetesatlas> (accessed May 4th 2013).
12
13
14 37. Gao XH, Winsey S, Li G, et al. HLA-DR and DQ polymorphisms in bullous
15 pemphigoid from northern China. *Clinical and experimental dermatology* 2002; 27(4): 319-
16 21.
17
18
19
20 38. Hutchinson MS, Joakimsen RM, Njolstad I, et al. Effects of Age and Sex on Estimated
21 Diabetes Prevalence Using Different Diagnostic Criteria: The Tromso OGTT Study.
22 *International journal of endocrinology* 2013; 613475.
23
24
25 39. Stene LC, Midthjell K, Jenum AK, et al. Prevalence of diabetes mellitus in Norway.
26 *Tidsskr Nor Laegrforen* 2004; 124 (11): 1511-4.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10 **Figure legends**
11
12

13
14 -----Figure 1 colour -----
15


16
17
18 -----Figure 1 black and white -----
19

20
21
22 -----Figure 2 colour -----
23
24

25
26
27 -----Figure 2 black and white -----
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1. Prevalence of different risk markers in participants with Mets. Men.
N= 2008 Euro and N= 1043 NIH



150x133mm (300 x 300 DPI)

Figure 2 . Prevalence of different risk markers in participants with MetS. Women .
N= 2311 Euro and N= 1679 NIH



165x169mm (300 x 300 DPI)



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of cross-sectional studies

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	p 1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	P 2
Introductionp 4			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	P 4
Objectives	3	State specific objectives, including any prespecified hypotheses	P 5
Methods			
Study design	4	Present key elements of study design early in the paper	P 5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	p 5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	P 5-6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	p 6 -8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	P 6 -8
Bias	9	Describe any efforts to address potential sources of bias	P 6-8
Study size	10	Explain how the study size was arrived at	P 5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	p 8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	P 8
		(b) Describe any methods used to examine subgroups and interactions	P 8
		(c) Explain how missing data were addressed	P 8
		(d) If applicable, describe analytical methods taking account of sampling strategy	Not applicable
		(e) Describe any sensitivity analyses	Not done
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	P 8-9 and Table 1 Not done
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest	P 8- 9 and Table 1 No missing data in the further analyzes
Outcome data	15*	Report numbers of outcome events or summary measures	Table 1 p 8
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Table 2 p 10, table 3 p 12 fig 1 and 2 p 11 Not relevant
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Not done
Discussion			
Key results	18	Summarise key results with reference to study objectives	P 13 - 16
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	P 16
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	P 14 -16
Generalisability	21	Discuss the generalisability (external validity) of the study results	P 16
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	P 17

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

BMJ Open

The prevalence of metabolic syndrome and diabetes mellitus in Sami and Norwegian populations. The SAMINOR- a cross sectional study.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2015-009474.R2
Article Type:	Research
Date Submitted by the Author:	14-Jan-2016
Complete List of Authors:	Broderstad, Ann Ragnhild; Uit the Arctic University of Norway, Centre for Sami Health Research, Faculty of Health Melhus, Marita; Uit the Arctic University of Norway, Centre of Sami Health research, Faculty of Health
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Diabetes and endocrinology, Epidemiology, Public health, Nutrition and metabolism
Keywords:	Hypertension < CARDIOLOGY, General diabetes < DIABETES & ENDOCRINOLOGY, General endocrinology < DIABETES & ENDOCRINOLOGY, Lipid disorders < DIABETES & ENDOCRINOLOGY, EPIDEMIOLOGY

SCHOLARONE™
Manuscripts

Original Article**The prevalence of metabolic syndrome and diabetes mellitus in Sami and Norwegian populations. The SAMINOR-a cross sectional study.****Authors:**Ann Ragnhild Broderstad ^{1,2}Marita Melhus ¹

1. Centre for Sami Health Research, University of Tromsø The Arctic University of Norway

2. Medical Department, University Hospital of North Norway, Harstad

Contact details:

Ann Ragnhild Broderstad

Centre for Sami Health Research

University of Tromsø The Arctic University of Norway

N-9037 Tromsø

Norway

e-mail: Ann.Ragnhild.Broderstad@uit.no

Telephone +47 776 44000 / +47 78 46 89 00 Fax +47 78 46 89 10/ +47 76985021

Running head; Metabolic syndrome and diabetes among Sami and non-Sami

Keywords Metabolic, obesity, Sami, SAMINOR, diabetes

Words 3331

Tables 3

Figures 2

Abstract

Objectives

Metabolic syndrome (MetS) is recognized as a reliable long-term predictor of adverse health outcomes known. Elevated prevalence rates of MetS and chronic lifestyle diseases have been documented in different indigenous groups. We wanted to evaluate the prevalence of MetS and diabetes mellitus in relation to ethnicity in Northern Norway. In addition, we discussed different cut-off values for waist circumference (WC) and what impact this has on the prevalence of MetS.

Material and methods

SAMINOR is a population based study of health and living conditions in areas home to both Sami and non-Sami populations. The survey was carried through in 2003 – 2004. All eligible residents in specific age groups were invited. In total, 16,538 males and females aged 36-79 participated and gave informed consent for medical research.

Results

This study involved a total of 7,822 female and 7,290 male participants. Sami affiliation was reported by 5,141 participants (34 per cent). The prevalence of MetS was high in both ethnic groups independent of which WC cut off values used. No ethnic differences in prevalence of diabetes mellitus was demonstrated. However, ethnicity appeared to affect diabetes treatment and was more in use among Sami women compared to the non-Sami.

Conclusions

In this study it was no ethnic differences in diabetes prevalence, but ethnicity appeared to affect diabetes treatment. Tablet treatment was more common in use among Sami women compared to non-Sami women. We demonstrated a high share of negative metabolic components. These metabolic components have important health implications. Therefore, determining preventive initiatives is important in the primary and specialist health care

1
2
3 system. These initiatives must be made culture and linguistic specific, in order to reduce
4
5 differences and improve health status in the whole population.
6
7
8
9
10

11 12 13 **Strengths and limitations of this study**

- 14
15 • The SAMINOR study is the first survey to report on the prevalence of diabetes and
16
17 MetS in a large geographic area of North Norway including both the indigenous and
18
19 the non-indigenous population.
20
- 21
22 • The large sample size allowed for detailed analysis of diabetes and MetS in Sami and
23
24 non-Sami populations of rural North Norway.
25
- 26
27 • The survey has a relatively high response rate.
28
- 29
30 • Categorizing people based on ethnicity is a contentious practice. Different studies use
31
32 different criteria of ethnicity, which makes it difficult to compare results.
33
- 34
35 • Cross-sectional data cannot assess the effect of lifestyle on the incidence of MetS, and
36
37 longitudinal cohort studies are therefore needed.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **The prevalence of metabolic syndrome and diabetes mellitus in Sami and Norwegian**
4 **populations. The SAMINOR study-a cross sectional study.**
5
6
7

8 **Introduction**
9

10 Chronic disease has become a global problem and a burden on health care services, reaching
11 epidemic proportions. In Norway, as well as internationally, the great majority of patients in
12 health care systems are living with chronic disease.[1-2] Cardiovascular disease (CVD), type
13 2 diabetes mellitus (T2DM), cancer and chronic obstructive pulmonary disease (COPD) are the
14 most common causes of hospitalization and premature death.[3] Unfavorable health factors
15 such as obesity, insulin resistance, dyslipidemia and hypertension are known to elevate risks
16 of developing CVD and T2DM. Metabolic syndrome (MetS) indicates a cluster of these risk
17 factors. [4-5] MetS is generally recognized as a reliable long-term predictor of adverse health
18 outcomes.[6] Further, MetS has been recognized as a growing, global public health problem.
19 .[7] In addition, several studies demonstrate MetS to be associated with elevated cancer
20 risk.[8-9]
21
22
23
24
25
26
27
28
29
30
31
32
33
34

35 Information on the prevalence of chronic disease in various ethnicities of North Norway
36 remains sparse. The Sami, Kven and Norwegian ethnic groups are recognized as having
37 inhabited the region in centuries; the Norwegian government acknowledges the Sami people
38 as the indigenous people of Norway. The Norwegian health authorities have little systematic
39 knowledge about health status and living conditions among the Sami. National health -and
40 medical registers contribute to comprehensive information and knowledge about health-
41 related lifestyle and disease prevalence. However, information about ethnic background is not
42 permitted by law, in these registers nor in patient's medical records. Therefore, no reliable or
43 updated demographic records on the Sami exists that can be used for health research purposes.
44 Several epidemiological studies have documented elevated prevalence rates for chronic
45 lifestyle diseases in a number of different minority groups.[5, 10 -11] Although such disorders
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 have emerged quite recently in indigenous populations — mainly due to changes in lifestyle
4 and diet — they are, however, prevalent in several indigenous populations.[12-13]

5
6
7 Publications from the SAMINOR study of North Norway demonstrate that the prevalence of
8 obesity was high in the survey population, especially among Sami women.[14-15]

9
10
11 In order to evaluate the health of indigenous and non-indigenous populations of Norway
12 (inhabiting the same geographic area) it was necessary to conduct an epidemiological survey.
13
14 The present study aims to evaluate the prevalence of MetS and diabetes mellitus in Sami and
15 non-Sami populations residing in selected areas of North Norway. In addition, we will discuss
16 different cut-off values for waist circumference (WC) and what impact this has on the
17 prevalence of MetS.
18
19
20
21
22
23
24

25 **Methods**

26 *The SAMINOR study*

27
28
29 The cross-sectional data is derived from the SAMINOR study of 2003–2004 (SAMINOR 1).
30
31 The SAMINOR study was conducted by The Centre for Sami Health Research, Department
32 of Community Medicine, UiT The Arctic University of Norway, in collaboration with the
33 National Screening Program for Cardiovascular Diseases. The survey is described in detail
34 elsewhere.[16]
35
36
37
38
39

40 *The study sample*

41
42 All eligible residents aged 30 and 36–79 years registered in the Central Population Register
43 in 24 selected municipalities were invited regardless of ethnic background (n=27,987). Due to
44 a low response rate among those aged 30 years, our analyses were restricted to the age
45 interval 36 –79 years (n=27,151). In total, 16,538 males and females aged 36 –79
46 participated and gave informed consent for medical research. The response rate was 61 per
47 cent. Data was obtained from physical tests and blood samples. Information on ethnicity, and
48 the different diagnostic tools for MetS, were available for 15,112 participants.
49
50
51
52
53
54
55
56
57
58
59
60

Questionnaire design

An invitation was mailed several weeks before the survey arrived the municipality. The invitation contained information about the time and place, together with a five-page questionnaire. Those who agreed to attend the screening returned the questionnaire to the Norwegian Institute of Public health. These participants received later an invitation to the clinical examination. After the consultation the participants were asked to complete a new questionnaire. Information regarding ethnicity, disease and lifestyle were collected using these two self-administrated questionnaires. The questionnaires were translated into the three main Sami languages, Northern, Lule and South Sami languages. However, as only 1.6% of the participants chose to use the Sami version of the questionnaire, any language problems are probably of little importance in this study. Ethnicity was measured using the following questions: "*What language(s) do/did you, your parents and your grandparents use at home?*" The questions were to be answered separately for each relative. The available responses were: "Norwegian", "Sami", "Kven" and "Other". Multiple answers were allowed. Providing the same response options we also asked: "*What is your, your father's and your mother's ethnic background?*" The respondents also reported whether they considered themselves to be Norwegian, Sami, Kven or other (self-perceived ethnicity). We refer to Lund et al (16) for full description of the ethnicity and language questions. Based on these variables we generated two categories of ethnicity: "Sami" and "Non-Sami". Participants reporting at least one Sami identity mark (Sami language spoken by the respondent or at least one parent or grandparent, or Sami ethnic background or self-perceived Sami ethnicity) were placed in the category "Sami". The "Non-Sami" comprised the remainder of the participants.

The study was accredited by the Regional Board of Research Ethics in Northern Norway, and by the Board's Sami Consultant. The survey is in accordance with the Helsinki Declaration of

1
2
3 1975. The National Data Protection Authority (*Datatilsynet*) approved the use of personal
4 information and the study are registered with the number 2002/1525-2.
5
6

7 *Screening*

8
9 Due to the large size of the study sample participants were examined at different times of day.
10
11 This meant that it was not possible to ask participants to be fasting prior to arrival. Non-
12
13 fasting blood samples were obtained at the research station. Blood samples were drawn by
14
15 venopuncture at normal venous pressure in sitting position. Serum was separated at the station
16
17 within 1.5 hours. Serum was sent by overnight mail to laboratories in Oslo and Tromsø. The
18
19 laboratory analyses are described in detail elsewhere.[17]
20
21

22
23 Body mass index (BMI) was based on measurements of weight and height, and expressed as
24
25 body weight in kilograms/(body height in meters)². BMI categories were defined according to
26
27 guidelines from The World Health Organization (WHO); 'underweight' corresponding to a
28
29 BMI < 18.5 kg/m², 'standard weight' in the range 18.5–24.9 kg/m², 'overweight' in the range 25
30
31 – 29.9 kg/m² and 'obese' ≥ 30 kg/m². [18]
32
33

34
35 Waist circumference (WC), which is used to identify abdominal obesity, was measured (to the
36
37 nearest centimeter) at the umbilicus with the participant standing erect. Two different WC
38
39 cut-off values were applied to define abdominal obesity to enable the comparison of how the
40
41 corresponding values influenced the subsequently calculated prevalence of MetS. The US
42
43 National Institute of Health (NIH) Clinical Practice Guidelines defines central/abdominal
44
45 obesity as WC ≥ 102 cm in males and WC ≥ 88 cm in females.[19] In addition, abnormal WC
46
47 for European males are ≥ 94 cm and for females ≥ 80 cm. These figures are based on cross-
48
49 sectional data from Europeans and were included in the analyses.[18,20]
50
51

52 Trained personnel measured blood pressure, using Dinamap –R. automatic device.

53
54 Measurements were initiated after subjects had been seated for two minutes with their arms
55
56
57
58
59
60

1
2
3 resting on a table. Blood pressure was measured three times, with one- minute intervals. The
4
5 mean value of the second and third reading was used in the analysis.
6

7 8 *Diabetes mellitus*

9
10 Because all blood samples in the SAMINOR study were non-fasting, we used random plasma
11
12 glucose ≥ 11.1 mmol/L, in addition to self-reported diabetes and information about anti-
13
14 diabetic medication from a questionnaire to define diabetes mellitus. The question about
15
16 diabetes mellitus was; “Do you have or have you had diabetes?” The available responses
17
18 were “Yes” or “No”. Missing values were classified as “No”. In the absence of oral glucose
19
20 tolerance tests we used random plasma glucose ≥ 11.1 mmol/l as a substitute for elevated oral
21
22 glucose tolerance test.
23

24 25 *Metabolic syndrome*

26
27 Several attempts have been made at developing diagnostic criteria for the definition of MetS.
28
29 [21-23] In 2004, the International Diabetes Federation (IDF), the WHO and the National
30
31 Cholesterol Education Program Third Adult Treatment Panel (ATP III) produced a consensus
32
33 statement on the definition of MetS.[24] The latter definition requires central obesity and cut-
34
35 off points to be specified according to gender and ethnicity. Central obesity is most commonly
36
37 measured by WC; cut-off values are based on cross-sectional studies conducted in Europe,
38
39 The United States and Asia.[18-20, 25] The diagnostic tools are intended for clinical and
40
41 research purposes. The definition of MetS used in this article adheres to the IDF MetS
42
43 worldwide definition,[24]: Central obesity plus any two of four additional factors; Elevated
44
45 triglyceride level > 1.7 mmol/l, reduced HDL-cholesterol < 1.03 mmol/l in males and < 1.29
46
47 mmol/l in females, elevated blood pressure (systolic BP ≥ 130 or diastolic BP ≥ 85 mmHg)
48
49 and elevated fasting plasma glucose ≥ 11.1 mmol/l or previously diagnosed type 2 diabetes.
50
51

52 53 *Statistical analyses*

1
2
3 All analyses were stratified by gender. Sample characteristics were presented separately by
4 gender and ethnicity as mean values for continuous variables with corresponding 95 per cent
5 confidence intervals. Analyses of variance (ANOVA) were used for tests of ethnic
6 differences (Table 1). Differences according to diabetes mellitus and MetS prevalence were
7 tested by Chi-square tests (Tables 2 and 3). MetS prevalence was also stratified by age (Table
8 3). Logistic regression analyses were used to test for age influence on MetS with age as a
9 continuous variable (Table 3).

10
11 We used the SAS statistical software package, version 9.3 (SAS Institute Inc., Cary, NC,
12 USA).

13 14 15 16 17 18 19 20 21 22 23 24 25 **Results**

26
27 The current analysis involved a total of 7,822 female and 7,290 male participants. Sami
28 affiliation was reported by 5,141 participants (34 per cent). Table 1 shows gender-specific and
29 ethnicity-specific characteristics at enrolment in the study.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1 Sample characteristics by gender and ethnic group. (N= 15 112)

Men	Sami (N=2559)	Non-Sami (N=4731)	p-value ²
	Mean (95 % CI) ¹	Mean (95 % CI) ¹	
Age (yr)	55.0 (54.8-55.1)	54.8 (54.7-54.9)	0.584
Height (cm)	170.0 (170.0-170.2)	175.7 (175.6 – 175.8)	<0.0001
Weight (kg)	80.6 (80.4 – 80.7)	85.1 (85.0 – 85.3)	<0.0001
BMI (kg/m ²)	27.8 (27.7-27.9)	27.5 (27.5 – 27.6)	0.009
WC (cm)	93.2 (93.0 – 93.3)	95.0 (94.9 – 95.2)	<0.0001
Non-fasting glu (mmol/L)	5.8 (5.8- 5.8)	5.8 (5.7 – 5.8)	0.313
HDL-chol (mmol/l)	1.27 (1.26 – 1.28)	1.25 (1.25 – 1.26)	0.115
LDL- chol (mmol/L)	3.87 (3.86 – 3.89)	3.80 (3.79 – 3.81)	0.004
Cholesterol (mmol/l)	5.98 (5.96- 5.99)	5.90 (5.90 – 5.90)	0.001
Triglycerids (mmol/l)	1.86 (1.85 – 1.88)	1.86 (1.85 – 1.88)	0.970
Systolic BT (mmHg)	135 (135 – 135)	134 (134 -134)	0.168
Diastolic BT (mmHg)	78 (78 -78)	78 (78 – 78)	0.182
Women	Sami (N=2581)	Non-Sami (N=5241)	p-value
	Mean (95 % CI)¹	Mean (95 % CI)¹	
Age (yr)	54.2 (54.1 – 54.4)	54.5 (54.4 – 54.6)	0.277
Height (cm)	157.3 (157.2 – 157.4)	162.6 (162.6 – 162.7)	<0.0001
Weight (kg)	69.7 (69.6 – 69.9)	72.1 (71.9 -72.2)	<0.0001
BMI (kg/m ²)	28.2 (28.1 – 28.3)	27.3 (27.2 – 27.3)	<0.0001
WC (cm)	86.0 (85.9 – 86.2)	85.5 (85.4 – 85.6)	0.053
Non-fasting glu (mmol/L)	5.66 (5.63 – 5.68)	5.57 (5.55 – 5.58)	0.018
HDL- chol (mmol/l)	1.45 (1.44 – 1.45)	1.49 (1.49 – 1.50)	<0.0001
LDL- chol (mmol/L)	3.82 (3.81 – 3.83)	3.81 (3.80 – 3.82)	0.707
Cholesterol (mmol/l)	5.98 (5.96 – 5.99)	5.99 (5.98 – 6.00)	0.617
Triglycerids (mmol/l)	1.54(1.56 – 1.59)	1.53 (1.52 – 1.54)	0.044
Systolic BT (mmHg)	130 (129 – 130)	130 (130 -131)	0.125
Diastolic BT (mmHg)	72 (72 -72)	73 (73 -73)	0.008

¹ 95% confidence interval² test of differences , ANOVA, for between Sami versus non-Sami

The mean BMI was greater in Sami males, whereas the mean WC was greater in non-Sami males. Sami females, however, showed significantly greater values for mean BMI, WC and lipids.

Table 2 shows the prevalence of diabetes in Sami and non-Sami participants.

Table 2. Prevalence of diabetes mellitus in the SAMINOR study (N=15112)

Men	Sami	Non-Sami	p-value
	(N=2559)	(N=4731)	
	n (%)	n (%)	
Diabetes prevalence	132 (5.2)	212 (4.5)	0.19 ¹
Insulin treatment	13 (0.5)	31 (0.7)	
Tablet treatment	45 (1.8)	87 (1.8)	
Insulin and tablet treatment	25 (1.0)	21 (0.4)	
Non-treatment	49 (1.9)	73 (1.5)	
Non-diabetes	2427 (33.3)	4519 (95.5)	0.05 ²
Women	Sami	Non-Sami	p-value
	(N=2581)	(N=5241)	
	n (%)	n (%)	
Diabetes prevalence	129 (5.0)	220 (4.2)	0.11 ¹
Insulin treatment	13 (0.5)	29 (0.6)	
Tablet treatment	61 (2.4)	71 (1.6)	
Insulin and tablet treatment	20 (0.8)	38 (0.7)	
Non-treatment	35 (1.4)	82 (1.6)	
Non-diabetes	2452(95.0)	5021 (95.8)	0.025 ²

¹ Chi-square test for differences in diabetes prevalence among Sami versus non-Sami

² Chi-square test for differences in treatment level among Sami versus non-Sami

No differences in prevalence of diabetes mellitus was demonstrated between ethnic groups, however, ethnicity appeared to affect diabetes treatment. Particularly it was more common to use tablet treatments among Sami women compared with non-Sami women. Among Sami men, however, a combination of tablet and insulin treatment was frequently in use compared with non-Sami men.

The prevalence of the various diagnostic tools for MetS is presented in Figures 1 (males) and 2 (females).

1
2
3 ----Figure 1 -----
4
5
6

7 ----Figure 2 -----
8
9
10
11
12
13
14
15
16
17

18 The most prevalent risk marker for MetS (aside from central obesity) was the presence of
19 elevated systolic blood pressure and high triglyceride levels independent of gender and
20 ethnicity.
21
22
23

24 Table 3 presents the prevalence of MetS according to WC cut-off points based on European
25 and NIH values.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 3. Prevalence of MetS among Sami and non-Sami, by age groups and gender. N= 15112 participants

	European cut off of WC		p-value ¹	NIH cut off of WC		p-value ¹
	Sami (N=650) n (%)	Non-Sami (N=917) n (%)		Sami (N=315) n (%)	Non-Sami (N=728) n (%)	
Men						
36-49 yr	194 (22.3)	429 (26.0)	0.038	89 (10.2)	203 (12.3)	0.118
50-59 yr	229 (27.2)	440 (29.7)	0.202	115 (13.7)	238 (16.1)	0.121
60-79 yr	227 (26.9)	489 (30.6)	0.055	111 (13.1)	287 (18.0)	0.002
p-value ²	0.029	<0.0001		0.05	<0.0001	
	Sami (N=790) n (%)	Non-Sami (N=1521) n (%)		Sami (N=588) n (%)	Non-Sami (N=1091) n (%)	
Women						
36-49 yr	232 (24.4)	369 (19.1)	0.006	161 (16.2)	263 (13.6)	0.056
50-59 yr	248 (31.5)	455 (29.4)	0.291	177 (22.5)	309 (20.0)	0.155
60-79 yr	310 (38.7)	697 (39.6)	0.641	250 (31.2)	519 (29.5)	0.393
p-value ²	0.004	<0.0001		<0.0001	<0.0001	

¹ Chi-square tests for differences in MetS prevalence of Sami versus non-Sami

² Age effect tested by logistic regression with age as a continuous variable

In each age bracket the results are stratified according to ethnicity (Sami and non-Sami).

Based on the European WC cut-off points, prevalence of MetS was higher in non-Sami participants in the age bracket 36-49 years. However, when applying the NIH WC cut-off point, a significantly lower prevalence was found for Sami males in the top age group.

1
2
3 Non-Sami males showed a higher overall prevalence of MetS (in comparison to Sami males)
4
5 for both WC cut-off values. In females ethnicity was not significant overall; however when
6
7 stratified by age, a significantly higher prevalence of MetS in the younger Sami females (in
8
9 comparison to non-Sami females) was found — when applying the European WC cut-off
10
11 value. The prevalence of MetS increased with age regardless of gender and ethnicity. The
12
13 proportion of women with all four risk markers was almost twice as large within the Sami
14
15 population (in comparison to non-Sami females) for both WC cut-off values (not shown). For
16
17 males, ethnicity appeared not to affect the number of risk markers found.
18
19
20
21
22

23 Discussion

24
25 The prevalence of MetS was high in both ethnic groups. No differences in prevalence of
26
27 diabetes mellitus was demonstrated between ethnic groups. It was more common to give
28
29 treatment for diabetes to both Sami men and women compared to the non-Sami participants.
30
31 The two different WC cut-off values greatly influenced the measured prevalence of MetS.
32
33 The present study demonstrates that ethnicity is a significant factor for MetS in participants
34
35 belonging to the lowest age bracket.
36
37

38 The two different WC cut-off values greatly influenced the measured prevalence of MetS.
39
40 The present study demonstrates that ethnicity is a significant factor for MetS in participants
41
42 belonging to the lowest age bracket. In the case of males aged between 36 and 49, MetS is
43
44 less prevalent in the Sami population (in comparison to non-Sami). For females in the same
45
46 age bracket, however, MetS is more prevalent in the Sami population. When the NIH cutoffs
47
48 were used, we found that — in the highest age bracket — the non-Sami males showed
49
50 significantly higher prevalence of MetS in comparison to Sami males. The prevalence of
51
52 MetS increased significantly by age in both ethnic groups, regardless of which WC cut-off
53
54 values were used.
55
56
57
58
59
60

1
2
3 In general, overweight and obesity are common among the participants in the SAMINOR
4 study. From earlier publications based on the SAMINOR study, central obesity has been
5 shown to be more common in Sami females.[15,26] General obesity in Sami females has also
6 been discussed by Njølstad et al (1998).[27] However, obesity rates were high in non-Sami
7 females as well.[14] For males, central obesity occurred more frequently in the non-Sami
8 population relative to the Sami population.[14-15]

9
10 MetS has several different definitions, making it difficult to directly compare and contrast
11 prevalence found in different surveys. WC is the most significant measurement of both central
12 obesity and fat distribution, according to The International Diabetes Federation (IDF).[28]

13
14 The group that produced the consensus statement on the definition of MetS in 2004
15 recommended that gender and ethnicity should be the basis for classification of cut-off points.
16 [24] The existing values are based on cross-sectional population survey data from the
17 respective countries. How to define the WC cut-off point in the various indigenous
18 populations has not yet been established; however, an immediate response would be to
19 perform cross-sectional population surveys within indigenous societies. In our study two
20 different cut-off points were used in order to facilitate comparison. The European cut-off
21 values doubled the prevalence of MetS in males and increased prevalence by more than 40 per
22 cent in females (compared to values found when applying NIH WC cut-off values). This was
23 the case in both ethnic groups. But the question of what the WC values should be in terms of
24 optimal prediction of prospective disease in the SAMINOR sample remains unanswered. A
25 follow-up study could provide better answers to questions regarding disease development.
26 Irrespective of cut-off values, elevated blood pressure was the most frequent MetS component
27 present in obese participants. These findings were also demonstrated in a collaborative
28 analysis of ten large cohort studies in Europe.[29] In the ten studies included, obesity
29 coincided with hypertension in up to 85 per cent of cases.

1
2
3 The presence of MetS, as well as its individual components, however, shows considerable
4 variance between populations. Several studies of MetS have been performed in circumpolar
5 areas, such as in indigenous peoples of Alaska, Canada and Greenland.[30-32] American
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The presence of MetS, as well as its individual components, however, shows considerable variance between populations. Several studies of MetS have been performed in circumpolar areas, such as in indigenous peoples of Alaska, Canada and Greenland.[30-32] American Indians and Aboriginal Canadians represent populations in which MetS, obesity and T2DM are becoming more prevalent. [13,30] MetS is also frequently occurring in Greenland's Inuit population.[32] A health survey in Greenland showed that central adiposity and obesity were more prevalent in the Inuit population when compared to the corresponding Danish population, but was not associated with the same degree of metabolic disturbance as in the general Danish population.[33] Yet it is debatable which factors in the cluster of MetS are the most significant in the development of chronic lifestyle diseases.

There is a significant relation between T2DM and MetS; the syndrome itself is not a disease, but consists of a cluster of factors that increase the risk for developing diseases. Thus we prefer to include diabetes in this article to demonstrate the link between the health indicator MetS and diabetes mellitus.[24] In the SAMINOR study diabetes mellitus was identified using a questionnaire, in addition to measured random plasma glucose ≥ 11.1 mmol/L in participants whom did not report diabetes mellitus. As the study had a large number of participants, up to 140 per day, conducting two-hour plasma glucose tolerance tests was considered infeasible. The portable HbA1c instruments available in 2003-2004 were inadequate for conducting HbA1C measurements at rural research stations. In addition, the survey was performed in provincial areas with long distances to the medical laboratory. Our analyses do not differentiate between type 1 and 2 diabetes mellitus due to insufficient information provided by the questionnaire. However, eight of ten diabetes cases in Norway are T2DM.[34] Also, globally, around 80 per cent of diabetes cases are T2DM,[35-37] giving a prevalence rate of 8.3 per cent. This figure is expected to increase due to lifestyle changes. [36] Diabetes prevalence in our study was between four and five percent, which is a lower

1
2
3 rate than the prevalence rate found in the urban population residing in 2007—2008 in the city
4 of Tromsø (8.5%) [38]. This study encompassed participants aged between 30 and 87, with a
5 mean age of 61. However, in the Tromsø study, fasting plasma glucose, two-hour plasma
6 glucose and HbA1c was measured. It is therefore likely that the present study underreports the
7 diabetes prevalence maybe as much as up to 50 percent. The significance of treatment
8 differences between ethnic groups has not been reported earlier and is difficult to explain.
9 These findings will therefore be addressed in future research.
10
11
12
13
14
15
16
17

18 *Strengths*

19
20 Our study is the first survey to report on the prevalence of diabetes and MetS in a large
21 geographic area of North Norway including both the indigenous and the non-indigenous
22 population. The large sample size allowed for detailed analysis of diabetes and MetS in Sami
23 and non-Sami populations of rural North Norway; it also reduces the influence of random
24 errors, which cannot fully be controlled for. The survey had a relatively high response rate.
25 Unquestionably, one of the strengths of the study was that clinical data — such as central
26 obesity (upon which MetS relies) — were collected by direct measurement and conducted by
27 trained personnel, providing reliable estimates of obesity prevalence in the participating
28 cohort.
29
30
31
32
33
34
35
36
37
38
39

40 *Limitations*

41
42 The cross-sectional study design is suitable for the examination of associations in order to
43 generate hypotheses that may be explored in longitudinal studies. Conversely, however, the
44 design prevents the establishment of causality. Due to the nature of the design, people with
45 severe disease may be missed because they are diseased at home, in long-term hospitalization
46 or having died in the time since the sample list was prepared (i.e., selection bias). The
47 SAMINOR study has used questionnaires to survey self-reported diseases. This approach
48 cannot detect people with undiagnosed symptoms and is limited by recall recall bias. In
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Norway, it is estimated between 90 00 to 120 000 people with diabetes and nearly as many
4
5 have undiagnosed disease. [39]
6

7
8 Categorizing people based on ethnicity is a contentious practice. Different studies use
9
10 different criteria of ethnic categorization, which makes it difficult to compare results. Our
11
12 definition of the Sami group is rather weak. This may have influenced our results. Since there
13
14 are no national records with information om ethnic background, it is impossible to know if the
15
16 response rate among Sami and non-Sami are different. We are therefore unable to assess
17
18 whether differences in participation have influenced the observed disease burden.
19

20
21 In summary, cross-sectional studies may be used in the measurement of the burden of disease
22
23 in a population. However, cross-sectional data cannot assess the effect of lifestyle on the
24
25 incidence of MetS, and longitudinal cohort studies are therefore needed.
26

27 **Conclusion**

28
29 Without question, the prevalence rates for several negative health factors were high in the
30
31 Sami and non-Sami population. Overweight and obesity were common, especially in the case
32
33 of Sami females. No differences in prevalence of diabetes mellitus was demonstrates between
34
35 ethnic groups. However, ethnicity appeared to affect diabetes treatment and was significantly
36
37 more frequent in use among Sami women compared to the non-Sami women. However, the
38
39 prevalence of MetS were in general high among participants in the SAMINOR study, with the
40
41 highest prevalence for the European cut off values. The syndrome has important health
42
43 implication but a cross sectional study cannot be used to validate the best ethnic specific
44
45 values for WC used in the definition of MetS and more data on this issue must be obtained. In
46
47 addition, determining preventive initiatives is important in the primary and specialist health
48
49 care system. These initiatives must be made culture and linguistic specific, in order to reduce
50
51 differences and improve health status in the whole population.
52
53
54
55
56
57
58
59
60

Acknowledgements

We are indebted to the participants of the SAMINOR study, without whom our research would be impossible. We would also like to thank the staff at the Department of Clinical Chemistry, University Hospital of North Norway, for technical assistance and careful evaluation of blood samples.

Summary Box

What is already known on this subject?

In Northern Norway the burden of obesity are especially high among female. Highest prevalence has been demonstrated among the Sami women. In this study we therefore examined several other risk factors for developing lifestyle diseases.

What this study adds?

This study showed a high prevalence of the metabolic syndrome among the population in north, independent of ethnic belonging. The burden of metabolic risk factors was highest among women, especially Sami women. Self-reported diabetes was between four and five percent which are slightly higher than the national prevalence rate. In the future, obesity and other metabolic risk factors will contribute to increase burden of lifestyle diseases among the Sami population. Two issues are therefore important to emphasize. Firstly, implement preventive interventions in the multicultural communities, as well as highlight research information to inhabitants and local and central authorities. Secondly, follow the health situation in each community with longitudinal studies to evaluate the effect of preventive efforts.

Contributorship statement

The idea behind the study was conceived by Ann R Broderstad. Both authors participated in the study concept and design. Ann R Broderstad drafted the manuscript. Both authors did the analyses of the tables and figures. Both authors reviewed and approved the final version of the manuscript.

Conflict of Interest

The authors declare that they have no conflict of interest.

Funding

Funding for this project was provided by the Norwegian Ministry of Health and Care Services.

Data sharing

No additional data available.

For peer review only

References

1. Banatvala N, Donaldson L. Chronic diseases in developing countries. *Lancet* 2007; 370(9605): 2076-8.
2. Dale AC, Nilsen TI, Vatten L, Midthjell K, Wiseth R. Diabetes mellitus and risk of fatal ischaemic heart disease by gender: 18 years follow-up of 74,914 individuals in the HUNT 1 Study. *European heart journal* 2007; 28(23): 2924-9.
3. Parajuli R, Bjerkaas E, Tverdal A, et al. The increased risk of colon cancer due to cigarette smoking may be greater in women than men. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology* 2013; 22(5): 862-71.
4. Grundy SM, Brewer HB, Jr., Cleeman JI, et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. *Circulation* 2004; 109(3): 433-8.
5. Simmons RK, Alberti KG, Gale EA, et al. The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. *Diabetologia* 2010; 53(4): 600-5.
6. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. *Diabetes care* 2005; 28(7): 1769-78.
7. Goldstein MR, Mascitelli L, Pezzetta F. On treating metabolic syndrome: emphasise lifestyle change. *The Lancet Oncology* 2010; 11(5): 415.
8. Ishino K, Mutoh M, Totsuka Y, Nakagama H. Metabolic syndrome: A novel high-risk state for colorectal cancer. *Cancer letters* 2012.
9. Russo A, Autelitano M, Bisanti L. Metabolic syndrome and cancer risk. *European journal of cancer* 2008; 44(2): 293-7.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
10. Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. *Endocrinology and metabolism clinics of North America* 2004; 33(2): 351-75, table of contents.
 11. Boyer BB, Mohatt GV, Plaetke R, et al. Metabolic syndrome in Yup'ik Eskimos: the Center for Alaska Native Health Research (CANHR) Study. *Obesity* 2007; 15(11): 2535-40.
 12. Liu J, Young TK, Zinman B, Harris SB, Connelly PW, Hanley AJ. Lifestyle variables, non-traditional cardiovascular risk factors, and the metabolic syndrome in an Aboriginal Canadian population. *Obesity* 2006; 14(3): 500-8.
 13. Schumacher C, Ferucci ED, Lanier AP, et al. Metabolic syndrome: prevalence among American Indian and Alaska native people living in the southwestern United States and in Alaska. *Metabolic syndrome and related disorders* 2008; 6(4): 267-73.
 14. Nystad T, Melhus M, Brustad M, Lund E. Ethnic differences in the prevalence of general and central obesity among the Sami and Norwegian populations: the SAMINOR study. *Scandinavian journal of public health* 2010; 38(1): 17-24.
 15. Broderstad AR, Melhus M, Lund E. Iron status in a multiethnic population (age 36-80 yr) in northern Norway: the SAMINOR study. *European journal of haematology* 2007; 79(5): 447-54.
 16. Lund E, Melhus M, Hansen KL, et al. Population based study of health and living conditions in areas with both Sami and Norwegian populations--the SAMINOR study. *International journal of circumpolar health* 2007; 66(2): 113-28.
 17. Nystad T, Utsi E, Selmer R, Brox J, Melhus M, Lund E. Distribution of apoB/apoA-1 ratio and blood lipids in Sami, Kven and Norwegian populations: the SAMINOR study. *Int J Circumpolar Health* 2008; 67(1): 67-81.
 18. WHO technical Report Series 894. Obesity: Preventing and Managing the Global Epidemic. World Health Organization : Geneva, Switzerland, 2000.; 1997. Report by the Secretariat http://apps.who.int/gb/ebwha/pdf_files/EB130/B130_9-en.pdf

- 1
2
3
4
5 19. Janssen I, Peter T, Katzmarzyk PT, Ross R. Body Mass Index, Waist Circumference,
6 and Health Risk Evidence in Support of Current National Institutes of Health Guidelines *Arch*
7
8 *Intern Med.* 2002;162(18):2074-2079.
9
10
11 20. Lean ME, Han TS, Morrison CE. Waist circumference as a measure for indicating
12 need for weight management. *Bmj* 1995; 311(6998): 158-61.
13
14 21. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus
15 and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional
16 report of a WHO consultation. *Diabetic medicine : a journal of the British Diabetic*
17 *Association* 1998; 15(7): 539-53.
18
19 22. Balkau B, Charles MA. Comment on the provisional report from the WHO
20 consultation. European Group for the Study of Insulin Resistance (EGIR). *Diabetic medicine :*
21 *a journal of the British Diabetic Association* 1999; 16(5): 442-3.
22
23 23. Cleeman JI. Executive summary of the third report of the National Cholesterol
24 Education Program (NCEP) expert panel on detection, evaluation, and treatment of high
25 blood cholesterol in adults (adult treatment panel III). *Journal of the American Medical*
26 *Association* 2001; 285(19): 2486 -97.
27
28 24. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome--a new world-wide definition. A
29 Consensus Statement from the International Diabetes Federation. *Diabetic medicine : a*
30 *journal of the British Diabetic Association* 2006; 23(5): 469-80.
31
32 25. Lin WY, Lee LT, Chen CY, et al. Optimal cut-off values for obesity: using simple
33 anthropometric indices to predict cardiovascular risk factors in Taiwan. *International journal*
34 *of obesity and related metabolic disorders : journal of the International Association for the*
35 *Study of Obesity* 2002; 26(9): 1232-8.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 26. Nystad T, Melhus M, Brustad M, Lund E. Ethnic differences in the prevalence of
4 general and central obesity among the Sami and Norwegian populations: the SAMINOR
5 study. *Scand J Public Health*; 38(1): 17-24.
6
7
8
9
10 27. Njolstad I, Arnesen E, Lund-Larsen PG. Cardiovascular diseases and diabetes mellitus
11 in different ethnic groups: the Finnmark study. *Epidemiology* 1998; 9(5): 550-6.
12
13
14 28. Carr DB, Utzschneider KM, Hull RL, et al. Intra-abdominal fat is a major determinant
15 of the National Cholesterol Education Program Adult Treatment Panel III criteria for the
16 metabolic syndrome. *Diabetes* 2004; 53(8): 2087-94.
17
18
19
20 29. van Vliet-Ostapchouk JV, Nuotio ML, Slagter SN, et al. The prevalence of metabolic
21 syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large
22 cohort studies. *BMC endocrine disorders* 2014; 14: 9.
23
24
25
26
27 30. Ley SH, Harris SB, Mamakeesick M, et al. Metabolic syndrome and its components as
28 predictors of incident type 2 diabetes mellitus in an Aboriginal community. *Cmaj* 2009;
29 180(6): 617-24.
30
31
32
33 31. Russell M, de Simone G, Resnick HE, Howard BV. The metabolic syndrome in
34 American Indians: the strong heart study. *J Cardiometab Syndr* 2007; 2(4): 283-7.
35
36
37
38 32. Jorgensen ME, Bjerregaard P, Gyntelberg F, Borch-Johnsen K. Prevalence of the
39 metabolic syndrome among the Inuit in Greenland. A comparison between two proposed
40 definitions. *Diabet Med* 2004; 21(11): 1237-42.
41
42
43
44 33. Jorgensen ME. Obesity and metabolic correlates among the Inuit and a general Danish
45 population. *Int J Circumpolar Health* 2004; 63 Suppl 2: 77-9.
46
47
48
49 34. Folkehelseinstituttet. Forekomst av diabetes - faktaark med helsestatistikk.
50 <http://www.fhi.no/artikler/?id=70814>
51
52
53
54 Folkehelseinstituttet; 2015.
55
56
57
58
59
60

- 1
2
3 35. Velho G, Froguel P, Mann J, Toeller M. Type 2 Diabetes. In: Ekoe J, Zimmet P,
4 Williams R, eds. *The Epidemiology of Diabetes mellitus*. Chichester, England: John Wiley &
5 Sons Ltd; 2001: 133-53.
6
7
8
9
10 36. Federation ID. *IDF Diabetes Atlas*. 6th edition [internet]. 2013.
11 <http://idf.org/diabetesatlas> (accessed May 4th 2013).
12
13
14 37. Gao XH, Winsey S, Li G, et al. HLA-DR and DQ polymorphisms in bullous
15 pemphigoid from northern China. *Clinical and experimental dermatology* 2002; 27(4): 319-
16 21.
17
18
19
20 38. Hutchinson MS, Joakimsen RM, Njolstad I, et al. Effects of Age and Sex on Estimated
21 Diabetes Prevalence Using Different Diagnostic Criteria: The Tromso OGTT Study.
22 *International journal of endocrinology* 2013; 613475.
23
24
25 39. Stene LC, Midthjell K, Jenum AK, et al. Prevalence of diabetes mellitus in Norway.
26 *Tidsskr Nor Laegrforen* 2004; 124 (11): 1511-4.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10 **Figure legends**
11
12

13
14 -----Figure 1 colour -----
15


16
17
18 -----Figure 1 black and white -----
19

20
21
22 -----Figure 2 colour -----
23
24

25
26
27 -----Figure 2 black and white -----
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1. Prevalence of different risk markers in participants with Mets. Men.
N= 2008 Euro and N= 1043 NIH



150x133mm (300 x 300 DPI)

Figure 2 . Prevalence of different risk markers in participants with MetS. Women .
N= 2311 Euro and N= 1679 NIH



165x169mm (300 x 300 DPI)



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of cross-sectional studies

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	p 1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	P 2
Introductionp 4			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	P 4
Objectives	3	State specific objectives, including any prespecified hypotheses	P 5
Methods			
Study design	4	Present key elements of study design early in the paper	P 5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	p 5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	P 5-6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	p 6 -8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	P 6 -8
Bias	9	Describe any efforts to address potential sources of bias	P 6-8
Study size	10	Explain how the study size was arrived at	P 5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	p 8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	P 8
		(b) Describe any methods used to examine subgroups and interactions	P 8
		(c) Explain how missing data were addressed	P 8
		(d) If applicable, describe analytical methods taking account of sampling strategy	Not applicable
		(e) Describe any sensitivity analyses	Not done
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	P 8-9 and Table 1 Not done
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest	P 8- 9 and Table 1 No missing data in the further analyzes
Outcome data	15*	Report numbers of outcome events or summary measures	Table 1 p 8
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Table 2 p 10, table 3 p 12 fig 1 and 2 p 11 Not relevant
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Not done
Discussion			
Key results	18	Summarise key results with reference to study objectives	P 13 - 16
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	P 16
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	P 14 -16
Generalisability	21	Discuss the generalisability (external validity) of the study results	P 16
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	P 17

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

BMJ Open

The prevalence of metabolic syndrome and diabetes mellitus in Sami and Norwegian populations. The SAMINOR- a cross sectional study.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2015-009474.R3
Article Type:	Research
Date Submitted by the Author:	03-Mar-2016
Complete List of Authors:	Broderstad, Ann Ragnhild; Uit the Arctic University of Norway, Centre for Sami Health Research, Faculty of Health Melhus, Marita; Uit the Arctic University of Norway, Centre of Sami Health research, Faculty of Health
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Diabetes and endocrinology, Epidemiology, Public health, Nutrition and metabolism
Keywords:	Hypertension < CARDIOLOGY, General diabetes < DIABETES & ENDOCRINOLOGY, General endocrinology < DIABETES & ENDOCRINOLOGY, Lipid disorders < DIABETES & ENDOCRINOLOGY, EPIDEMIOLOGY

SCHOLARONE™
Manuscripts

Original Article**The prevalence of metabolic syndrome and diabetes mellitus in Sami and Norwegian populations. The SAMINOR-a cross sectional study.****Authors:**Ann Ragnhild Broderstad ^{1,2}Marita Melhus ¹

1. Centre for Sami Health Research, University of Tromsø The Arctic University of Norway

2. Medical Department, University Hospital of North Norway, Harstad

Contact details:

Ann Ragnhild Broderstad

Centre for Sami Health Research

University of Tromsø The Arctic University of Norway

N-9037 Tromsø

Norway

e-mail: Ann.Ragnhild.Broderstad@uit.no

Telephone +47 776 44000 / +47 78 46 89 00 Fax +47 78 46 89 10/ +47 76985021

Running head; Metabolic syndrome and diabetes among Sami and non-Sami

Keywords Metabolic, obesity, Sami, SAMINOR, diabetes

Words 3331

Tables 3

Figures 2

Abstract

Objectives

Metabolic syndrome (MetS) is recognized as a reliable long-term predictor of adverse health outcomes known. Elevated prevalence rates of MetS and chronic lifestyle diseases have been documented in different indigenous groups. We wanted to evaluate the prevalence of MetS and diabetes mellitus in relation to ethnicity in Northern Norway. In addition, we discussed different cut-off values for waist circumference (WC) and what impact this has on the prevalence of MetS.

Material and methods

SAMINOR is a population based study of health and living conditions in areas home to both Sami and non-Sami populations. The survey was carried through in 2003 – 2004. All eligible residents in specific age groups were invited. In total, 16,538 males and females aged 36-79 participated and gave informed consent for medical research.

Results

This study involved a total of 7,822 female and 7,290 male participants. Sami affiliation was reported by 5,141 participants (34 per cent). The prevalence of MetS was high in both ethnic groups independent of which WC cut off values used. No ethnic differences in prevalence of diabetes mellitus was demonstrated. However, ethnicity appeared to affect diabetes treatment and was more in use among Sami women compared to the non-Sami.

Conclusions

In this study it was no ethnic differences in diabetes prevalence, but ethnicity appeared to affect diabetes treatment. Tablet treatment was more common in use among Sami women compared to non-Sami women. We demonstrated a high share of negative metabolic components. These metabolic components have important health implications. Therefore, determining preventive initiatives is important in the primary and specialist health care

1
2
3 system. These initiatives must be made culture and linguistic specific, in order to reduce
4
5 differences and improve health status in the whole population.
6
7
8
9
10

11 12 13 **Strengths and limitations of this study**

- 14
15 • The SAMINOR study is the first survey to report on the prevalence of diabetes and
16
17 MetS in a large geographic area of North Norway including both the indigenous and
18
19 the non-indigenous population.
20
- 21
22 • The large sample size allowed for detailed analysis of diabetes and MetS in Sami and
23
24 non-Sami populations of rural North Norway.
25
- 26
27 • The survey has a relatively high response rate.
28
- 29
30 • Categorizing people based on ethnicity is a contentious practice. Different studies use
31
32 different criteria of ethnicity, which makes it difficult to compare results.
33
- 34
35 • Cross-sectional data cannot assess the effect of lifestyle on the incidence of MetS, and
36
37 longitudinal cohort studies are therefore needed
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **The prevalence of metabolic syndrome and diabetes mellitus in Sami and Norwegian**
4 **populations. The SAMINOR study-a cross sectional study.**
5
6
7

8 **Introduction**
9

10 Chronic disease has become a global problem and a burden on health care services, reaching
11 epidemic proportions. In Norway, as well as internationally, the great majority of patients in
12 health care systems are living with chronic disease.[1-2] Cardiovascular disease (CVD), type
13 2 diabetes mellitus (T2DM), cancer and chronic obstructive pulmonary disease (COPD) are the
14 most common causes of hospitalization and premature death.[3] Unfavorable health factors
15 such as obesity, insulin resistance, dyslipidemia and hypertension are known to elevate risks
16 of developing CVD and T2DM. Metabolic syndrome (MetS) indicates a cluster of these risk
17 factors. [4-5] MetS is generally recognized as a reliable long-term predictor of adverse health
18 outcomes.[6] Further, MetS has been recognized as a growing, global public health problem.
19 .[7] In addition, several studies demonstrate MetS to be associated with elevated cancer
20 risk.[8-9]
21
22
23
24
25
26
27
28
29
30
31
32
33
34

35 Information on the prevalence of chronic disease in various ethnicities of North Norway
36 remains sparse. The Sami, Kven and Norwegian ethnic groups are recognized as having
37 inhabited the region in centuries; the Norwegian government acknowledges the Sami people
38 as the indigenous people of Norway. The Norwegian health authorities have little systematic
39 knowledge about health status and living conditions among the Sami. National health -and
40 medical registers contribute to comprehensive information and knowledge about health-
41 related lifestyle and disease prevalence. However, information about ethnic background is not
42 permitted by law, in these registers nor in patient's medical records. Therefore, no reliable or
43 updated demographic records on the Sami exists that can be used for health research purposes.
44 Several epidemiological studies have documented elevated prevalence rates for chronic
45 lifestyle diseases in a number of different minority groups.[5, 10 -11] Although such disorders
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 have emerged quite recently in indigenous populations — mainly due to changes in lifestyle
4 and diet — they are, however, prevalent in several indigenous populations.[12-13]

5
6
7 Publications from the SAMINOR study of North Norway demonstrate that the prevalence of
8 obesity was high in the survey population, especially among Sami women.[14-15]

9
10 In order to evaluate the health of indigenous and non-indigenous populations of Norway
11 (inhabiting the same geographic area) it was necessary to conduct an epidemiological survey.
12
13 The present study aims to evaluate the prevalence of MetS and diabetes mellitus in Sami and
14 non-Sami populations residing in selected areas of North Norway. In addition, we will discuss
15 different cut-off values for waist circumference (WC) and what impact this has on the
16 prevalence of MetS.
17
18
19
20
21
22
23
24

25 **Methods**

26 *The SAMINOR study*

27
28 The cross-sectional data is derived from the SAMINOR study of 2003–2004 (SAMINOR 1).
29
30 The SAMINOR study was conducted by The Centre for Sami Health Research, Department
31 of Community Medicine, UiT The Arctic University of Norway, in collaboration with the
32 National Screening Program for Cardiovascular Diseases. The survey is described in detail
33 elsewhere.[16]
34
35
36
37
38
39

40 *The study sample*

41
42 All eligible residents aged 30 and 36–79 years registered in the Central Population Register
43 in 24 selected municipalities were invited regardless of ethnic background (n=27,987). Due to
44 a low response rate among those aged 30 years, our analyses were restricted to the age
45 interval 36 –79 years (n=27,151). In total, 16,538 males and females aged 36 –79
46 participated and gave informed consent for medical research. The response rate was 61 per
47 cent. Data was obtained from physical tests and blood samples. Information on ethnicity, and
48 the different diagnostic tools for MetS, were available for 15,112 participants.
49
50
51
52
53
54
55
56
57
58
59
60

Questionnaire design

An invitation was mailed several weeks before the survey arrived the municipality. The invitation contained information about the time and place, together with a five-page questionnaire. Those who agreed to attend the screening returned the questionnaire to the Norwegian Institute of Public health. These participants received later an invitation to the clinical examination. After the consultation the participants were asked to complete a new questionnaire. Information regarding ethnicity, disease and lifestyle were collected using these two self-administrated questionnaires. The questionnaires were translated into the three main Sami languages, Northern, Lule and South Sami languages. However, as only 1.6% of the participants chose to use the Sami version of the questionnaire, any language problems are probably of little importance in this study. Ethnicity was measured using the following questions: "*What language(s) do/did you, your parents and your grandparents use at home?*" The questions were to be answered separately for each relative. The available responses were: "Norwegian", "Sami", "Kven" and "Other". Multiple answers were allowed. Providing the same response options we also asked: "*What is your, your father's and your mother's ethnic background?*" The respondents also reported whether they considered themselves to be Norwegian, Sami, Kven or other (self-perceived ethnicity). We refer to Lund et al (16) for full description of the ethnicity and language questions. Based on these variables we generated two categories of ethnicity: "Sami" and "Non-Sami". Participants reporting at least one Sami identity mark (Sami language spoken by the respondent or at least one parent or grandparent, or Sami ethnic background or self-perceived Sami ethnicity) were placed in the category "Sami". The "Non-Sami" comprised the remainder of the participants.

The study was accredited by the Regional Board of Research Ethics in Northern Norway, and by the Board's Sami Consultant. The survey is in accordance with the Helsinki Declaration of

1
2
3 1975. The National Data Protection Authority (*Datatilsynet*) approved the use of personal
4 information and the study are registered with the number 2002/1525-2.
5
6

7 *Screening*

8
9 Due to the large size of the study sample participants were examined at different times of day.
10
11 This meant that it was not possible to ask participants to be fasting prior to arrival. Non-
12
13 fasting blood samples were obtained at the research station. Blood samples were drawn by
14
15 venopuncture at normal venous pressure in sitting position. Serum was separated at the station
16
17 within 1.5 hours. Serum was sent by overnight mail to laboratories in Oslo and Tromsø. The
18
19 laboratory analyses are described in detail elsewhere.[17]
20
21

22
23 Body mass index (BMI) was based on measurements of weight and height, and expressed as
24
25 body weight in kilograms/(body height in meters)². BMI categories were defined according to
26
27 guidelines from The World Health Organization (WHO); 'underweight' corresponding to a
28
29 BMI < 18.5 kg/m², 'standard weight' in the range 18.5–24.9 kg/m², 'overweight' in the range 25
30
31 – 29.9 kg/m² and 'obese' ≥ 30 kg/m². [18]
32
33

34
35 Waist circumference (WC), which is used to identify abdominal obesity, was measured (to the
36
37 nearest centimeter) at the umbilicus with the participant standing erect. Two different WC
38
39 cut-off values were applied to define abdominal obesity to enable the comparison of how the
40
41 corresponding values influenced the subsequently calculated prevalence of MetS. The US
42
43 National Institute of Health (NIH) Clinical Practice Guidelines defines central/abdominal
44
45 obesity as WC ≥ 102 cm in males and WC ≥ 88 cm in females. [19] In addition, abnormal WC
46
47 for European males are ≥ 94 cm and for females ≥ 80 cm. These figures are based on cross-
48
49 sectional data from Europeans and were included in the analyses. [18,20]
50
51

52 Trained personnel measured blood pressure, using Dinamap –R. automatic device.

53
54 Measurements were initiated after subjects had been seated for two minutes with their arms
55
56
57
58
59
60

1
2
3 resting on a table. Blood pressure was measured three times, with one- minute intervals. The
4
5 mean value of the second and third reading was used in the analysis.
6

7 8 *Diabetes mellitus*

9
10 Because all blood samples in the SAMINOR study were non-fasting, we used random plasma
11
12 glucose ≥ 11.1 mmol/L, in addition to self-reported diabetes and information about anti-
13
14 diabetic medication from a questionnaire to define diabetes mellitus. The question about
15
16 diabetes mellitus was; “Do you have or have you had diabetes?” The available responses
17
18 were “Yes” or “No”. Missing values were classified as “No”. In the absence of oral glucose
19
20 tolerance tests we used random plasma glucose ≥ 11.1 mmol/l as a substitute for elevated oral
21
22 glucose tolerance test.
23

24 25 *Metabolic syndrome*

26
27 Several attempts have been made at developing diagnostic criteria for the definition of MetS.
28
29 [21-23] In 2004, the International Diabetes Federation (IDF), the WHO and the National
30
31 Cholesterol Education Program Third Adult Treatment Panel (ATP III) produced a consensus
32
33 statement on the definition of MetS.[24] The latter definition requires central obesity and cut-
34
35 off points to be specified according to gender and ethnicity. Central obesity is most commonly
36
37 measured by WC; cut-off values are based on cross-sectional studies conducted in Europe,
38
39 The United States and Asia.[18-20, 25] The diagnostic tools are intended for clinical and
40
41 research purposes. The definition of MetS used in this article adheres to the IDF MetS
42
43 worldwide definition,[24]: Central obesity plus any two of four additional factors; Elevated
44
45 triglyceride level > 1.7 mmol/l, reduced HDL-cholesterol < 1.03 mmol/l in males and < 1.29
46
47 mmol/l in females, elevated blood pressure (systolic BP ≥ 130 or diastolic BP ≥ 85 mmHg)
48
49 and elevated fasting plasma glucose ≥ 11.1 mmol/l or previously diagnosed type 2 diabetes.
50
51
52

53 54 *Statistical analyses*

1
2
3 All analyses were stratified by gender. Sample characteristics were presented separately by
4 gender and ethnicity as mean values for continuous variables with corresponding 95 per cent
5 confidence intervals. Analyses of variance (ANOVA) were used for tests of ethnic
6 differences (Table 1). Differences according to diabetes mellitus and MetS prevalence were
7 tested by Chi-square tests (Tables 2 and 3). MetS prevalence was also stratified by age (Table
8 3). Logistic regression analyses were used to test for age influence on MetS with age as a
9 continuous variable (Table 3).

10
11 We used the SAS statistical software package, version 9.3 (SAS Institute Inc., Cary, NC,
12 USA).

13 14 15 16 17 18 19 20 21 22 23 24 25 **Results**

26
27 The current analysis involved a total of 7,822 female and 7,290 male participants. Sami
28 affiliation was reported by 5,141 participants (34 per cent). Table 1 shows gender-specific and
29 ethnicity-specific characteristics at enrolment in the study.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1 Sample characteristics by gender and ethnic group. (N= 15 112)

Men	Sami (N=2559)	Non-Sami (N=4731)	p-value ²
	Mean (95 % CI) ¹		
Age (yr)	55.0 (54.8-55.1)	54.8 (54.7-54.9)	0.584
Height (cm)	170.0 (170.0-170.2)	175.7 (175.6 – 175.8)	<0.0001
Weight (kg)	80.6 (80.4 – 80.7)	85.1 (85.0 – 85.3)	<0.0001
BMI (kg/m ²)	27.8 (27.7-27.9)	27.5 (27.5 – 27.6)	0.009
WC (cm)	93.2 (93.0 – 93.3)	95.0 (94.9 – 95.2)	<0.0001
Non-fasting glu (mmol/L)	5.8 (5.8- 5.8)	5.8 (5.7 – 5.8)	0.313
HDL-chol (mmol/l)	1.27 (1.26 – 1.28)	1.25 (1.25 – 1.26)	0.115
LDL- chol (mmol/L)	3.87 (3.86 – 3.89)	3.80 (3.79 – 3.81)	0.004
Cholesterol (mmol/l)	5.98 (5.96- 5.99)	5.90 (5.90 – 5.90)	0.001
Triglycerids (mmol/l)	1.86 (1.85 – 1.88)	1.86 (1.85 – 1.88)	0.970
Systolic BT (mmHg)	135 (135 – 135)	134 (134 -134)	0.168
Diastolic BT (mmHg)	78 (78 -78)	78 (78 – 78)	0.182
Women	Sami (N=2581)	Non-Sami (N=5241)	p-value
	Mean (95 % CI) ¹		
Age (yr)	54.2 (54.1 – 54.4)	54.5 (54.4 – 54.6)	0.277
Height (cm)	157.3 (157.2 – 157.4)	162.6 (162.6 – 162.7)	<0.0001
Weight (kg)	69.7 (69.6 – 69.9)	72.1 (71.9 -72.2)	<0.0001
BMI (kg/m ²)	28.2 (28.1 – 28.3)	27.3 (27.2 – 27.3)	<0.0001
WC (cm)	86.0 (85.9 – 86.2)	85.5 (85.4 – 85.6)	0.053
Non-fasting glu (mmol/L)	5.66 (5.63 – 5.68)	5.57 (5.55 – 5.58)	0.018
HDL- chol (mmol/l)	1.45 (1.44 – 1.45)	1.49 (1.49 – 1.50)	<0.0001
LDL- chol (mmol/L)	3.82 (3.81 – 3.83)	3.81 (3.80 – 3.82)	0.707
Cholesterol (mmol/l)	5.98 (5.96 – 5.99)	5.99 (5.98 – 6.00)	0.617
Triglycerids (mmol/l)	1.54(1.56 – 1.59)	1.53 (1.52 – 1.54)	0.044
Systolic BT (mmHg)	130 (129 – 130)	130 (130 -131)	0.125
Diastolic BT (mmHg)	72 (72 -72)	73 (73 -73)	0.008

¹ 95% confidence interval² test of differences , ANOVA, for between Sami versus non-Sami

The mean BMI was greater in Sami males, whereas the mean WC was greater in non-Sami males. Sami females, however, showed significantly greater values for mean BMI, WC and lipids.

Table 2 shows the prevalence of diabetes in Sami and non-Sami participants.

Table 2. Prevalence of diabetes mellitus and diabetes treatment in the SAMINOR study (N=15112)

Men	Sami (N=2559)	Non-Sami (N=4731)	p-value
	n (%)	n (%)	
Diabetes prevalence	132 (5.2)	212 (4.5)	0.19 ¹
Insulin treatment	13 (0.5)	31 (0.7)	
Tablet treatment	45 (1.8)	87 (1.8)	
Insulin and tablet treatment	25 (1.0)	21 (0.4)	
Non-treatment	49 (1.9)	73 (1.5)	
Non-diabetes	2427 (33.3)	4519 (95.5)	0.05 ²
Women	Sami (N=2581)	Non-Sami (N=5241)	p-value
	n (%)	n (%)	

Diabetes prevalence	129 (5.0)	220 (4.2)	0.11 ¹
Insulin treatment	13 (0.5)	29 (0.6)	
Tablet treatment	61 (2.4)	71 (1.6)	
Insulin and tablet treatment	20 (0.8)	38 (0.7)	
Non-treatment	35 (1.4)	82 (1.6)	
Non-diabetes	2452(95.0)	5021 (95.8)	0.025 ²

¹ Chi-square test for differences in diabetes prevalence among Sami versus non-Sami

² Chi-square test for differences in treatment level among Sami versus non-Sami

No differences in prevalence of diabetes mellitus was demonstrated between ethnic groups, however, ethnicity appeared to affect diabetes treatment. Particularly it was more common to use tablet treatments among Sami women compared with non-Sami women. Among Sami men, however, a combination of tablet and insulin treatment was frequently in use compared with non-Sami men.

The prevalence of the various diagnostic tools for MetS is presented in Figures 1 (males) and 2 (females).

-----Figure 1 -----

-----Figure 2 -----

The most prevalent risk marker for MetS (aside from central obesity) was the presence of elevated systolic blood pressure and high triglyceride levels independent of gender and ethnicity.

Table 3 presents the prevalence of MetS according to WC cut-off points based on European and NIH values.

Table 3. Prevalence of MetS among Sami and non-Sami, by age groups and gender. N= 15112 participants

	European cut off of WC		p-value ¹	NIH cut off of WC		p-value ¹
	Sami (N=650) n (%)	Non-Sami (N=917) n (%)		Sami (N=315) n (%)	Non-Sami (N=728) n (%)	
Men						
36-49 yr	194 (22.3)	429 (26.0)	0.038	89 (10.2)	203 (12.3)	0.118
50-59 yr	229 (27.2)	440 (29.7)	0.202	115 (13.7)	238 (16.1)	0.121
60-79 yr	227 (26.9)	489 (30.6)	0.055	111 (13.1)	287	0.002

					(18.0)	
p-value ²	0.029	<0.0001		0.05	<0.0001	
	Sami (N=790) n (%)	Non-Sami (N=1521) n (%)		Sami (N=588) n (%)	Non-Sami (N=1091) n (%)	
Women						
36-49 yr	232 (24.4)	369 (19.1)	0.006	161 (16.2)	263 (13.6)	0.056
50-59 yr	248 (31.5)	455 (29.4)	0.291	177 (22.5)	309 (20.0)	0.155
60-79 yr	310 (38.7)	697 (39.6)	0.641	250 (31.2)	519 (29.5)	0.393
p-value ²	0.004	<0.0001		<0.0001	<0.0001	

¹ Chi-square tests for differences in MetS prevalence of Sami versus non-Sami

² Age effect tested by logistic regression with age as a continuous variable

In each age bracket the results are stratified according to ethnicity (Sami and non-Sami).

Based on the European WC cut-off points, prevalence of MetS was higher in non-Sami participants in the age bracket 36-49 years. However, when applying the NIH WC cut-off point, a significantly lower prevalence was found for Sami males in the top age group.

Non-Sami males showed a higher overall prevalence of MetS (in comparison to Sami males) for both WC cut-off values. In females ethnicity was not significant overall; however when stratified by age, a significantly higher prevalence of MetS in the younger Sami females (in comparison to non-Sami females) was found — when applying the European WC cut-off value. The prevalence of MetS increased with age regardless of gender and ethnicity. The proportion of women with all four risk markers was almost twice as large within the Sami population (in comparison to non-Sami females) for both WC cut-off values (not shown). For males, ethnicity appeared not to affect the number of risk markers found.

Discussion

1
2
3 The prevalence of MetS was high in both ethnic groups. No differences in prevalence of
4 diabetes mellitus was demonstrated between ethnic groups. It was more common to give
5 treatment for diabetes to both Sami men and women compared to the non-Sami participants.
6
7

8
9 The two different WC cut-off values greatly influenced the measured prevalence of MetS.
10

11 The present study demonstrates that ethnicity is a significant factor for MetS in participants
12 belonging to the lowest age bracket.
13

14
15 The two different WC cut-off values greatly influenced the measured prevalence of MetS.
16

17 The present study demonstrates that ethnicity is a significant factor for MetS in participants
18 belonging to the lowest age bracket. In the case of males aged between 36 and 49, MetS is
19 less prevalent in the Sami population (in comparison to non-Sami). For females in the same
20 age bracket, however, MetS is more prevalent in the Sami population. When the NIH cutoffs
21 were used, we found that — in the highest age bracket — the non-Sami males showed
22 significantly higher prevalence of MetS in comparison to Sami males. The prevalence of
23 MetS increased significantly by age in both ethnic groups, regardless of which WC cut-off
24 values were used.
25
26
27
28
29
30
31
32
33
34
35

36 In general, overweight and obesity are common among the participants in the SAMINOR
37 study. From earlier publications based on the SAMINOR study, central obesity has been
38 shown to be more common in Sami females.[15,26] General obesity in Sami females has also
39 been discussed by Njølstad et al (1998).[27] However, obesity rates were high in non-Sami
40 females as well.[14] For males, central obesity occurred more frequently in the non-Sami
41 population relative to the Sami population.[14-15]
42
43
44
45
46
47
48

49 MetS has several different definitions, making it difficult to directly compare and contrast
50 prevalence found in different surveys. WC is the most significant measurement of both central
51 obesity and fat distribution, according to The International Diabetes Federation (IDF).[28]
52
53
54

55 The group that produced the consensus statement on the definition of MetS in 2004
56
57
58
59
60

recommended that gender and ethnicity should be the basis for classification of cut-off points. [24] The existing values are based on cross-sectional population survey data from the respective countries. How to define the WC cut-off point in the various indigenous populations has not yet been established; however, an immediate response would be to perform cross-sectional population surveys within indigenous societies. In our study two different cut-off points were used in order to facilitate comparison. The European cut-off values doubled the prevalence of MetS in males and increased prevalence by more than 40 per cent in females (compared to values found when applying NIH WC cut-off values). This was the case in both ethnic groups. But the question of what the WC values should be in terms of optimal prediction of prospective disease in the SAMINOR sample remains unanswered. A follow-up study could provide better answers to questions regarding disease development. Irrespective of cut-off values, elevated blood pressure was the most frequent MetS component present in obese participants. These findings were also demonstrated in a collaborative analysis of ten large cohort studies in Europe.[29] In the ten studies included, obesity coincided with hypertension in up to 85 per cent of cases.

The presence of MetS, as well as its individual components, however, shows considerable variance between populations. Several studies of MetS have been performed in circumpolar areas, such as in indigenous peoples of Alaska, Canada and Greenland.[30-32] American Indians and Aboriginal Canadians represent populations in which MetS, obesity and T2DM are becoming more prevalent. [13,30] MetS is also frequently occurring in Greenland's Inuit population.[32] A health survey in Greenland showed that central adiposity and obesity were more prevalent in the Inuit population when compared to the corresponding Danish population, but was not associated with the same degree of metabolic disturbance as in the general Danish population.[33] Yet it is debatable which factors in the cluster of MetS are the most significant in the development of chronic lifestyle diseases.

1
2
3 There is a significant relation between T2DM and MetS; the syndrome itself is not a disease,
4
5 but consists of a cluster of factors that increase the risk for developing diseases. Thus we
6
7 prefer to include diabetes in this article to demonstrate the link between the health indicator
8
9 MetS and diabetes mellitus.[24] In the SAMINOR study diabetes mellitus was identified
10
11 using a questionnaire, in addition to measured random plasma glucose ≥ 11.1 mmol/L in
12
13 participants whom did not report diabetes mellitus. As the study had a large number of
14
15 participants, up to 140 per day, conducting two-hour plasma glucose tolerance tests was
16
17 considered infeasible. The portable HbA1c instruments available in 2003-2004 were
18
19 inadequate for conducting HbA1C measurements at rural research stations. In addition, the
20
21 survey was performed in provincial areas with long distances to the medical laboratory.
22
23 Our analyses do not differentiate between type 1 and 2 diabetes mellitus due to insufficient
24
25 information provided by the questionnaire. However, eight of ten diabetes cases in Norway
26
27 are T2DM.[34] Also, globally, around 80 per cent of diabetes cases are T2DM,[35-37] giving
28
29 a prevalence rate of 8.3 per cent. This figure is expected to increase due to lifestyle changes.
30
31 [36] Diabetes prevalence in our study was between four and five percent, which is a lower
32
33 rate than the prevalence rate found in the urban population residing in 2007—2008 in the city
34
35 of Tromsø (8.5%) [38]. This study encompassed participants aged between 30 and 87, with a
36
37 mean age of 61. However, in the Tromsø study, fasting plasma glucose, two-hour plasma
38
39 glucose and HbA1c was measured. It is therefore likely that the present study underreports the
40
41 diabetes prevalence maybe as much as up to 50 percent. The significance of treatment
42
43 differences between ethnic groups has not been reported earlier and is difficult to explain.
44
45 These findings will therefore be addressed in future research.
46
47
48
49
50

51 *Strengths*

52
53 Our study is the first survey to report on the prevalence of diabetes and MetS in a large
54
55 geographic area of North Norway including both the indigenous and the non-indigenous
56
57
58
59
60

1
2
3 population. The large sample size allowed for detailed analysis of diabetes and MetS in Sami
4
5 and non-Sami populations of rural North Norway; it also reduces the influence of random
6
7 errors, which cannot fully be controlled for. The survey had a relatively high response rate.
8
9 Unquestionably, one of the strengths of the study was that clinical data — such as central
10
11 obesity (upon which MetS relies) — were collected by direct measurement and conducted by
12
13 trained personnel, providing reliable estimates of obesity prevalence in the participating
14
15 cohort.
16

17 18 *Limitations* 19

20
21 The cross-sectional study design is suitable for the examination of associations in order to
22
23 generate hypotheses that may be explored in longitudinal studies. Conversely, however, the
24
25 design prevents the establishment of causality. Due to the nature of the design, people with
26
27 severe disease may be missed because they are diseased at home, in long-term hospitalization
28
29 or having died in the time since the sample list was prepared (i.e., selection bias). The
30
31 SAMINOR study has used questionnaires to survey self-reported diseases. This approach
32
33 cannot detect people with undiagnosed symptoms and is limited by recall bias. In
34
35 Norway, it is estimated between 90 000 to 120 000 people with diabetes and nearly as many
36
37 have undiagnosed disease. [39]
38

39
40 Categorizing people based on ethnicity is a contentious practice. Different studies use
41
42 different criteria of ethnic categorization, which makes it difficult to compare results. Our
43
44 definition of the Sami group is rather weak. This may have influenced our results. Since there
45
46 are no national records with information on ethnic background, it is impossible to know if the
47
48 response rate among Sami and non-Sami are different. We are therefore unable to assess
49
50 whether differences in participation have influenced the observed disease burden.
51
52
53
54
55
56
57
58
59
60

1
2
3 In summary, cross-sectional studies may be used in the measurement of the burden of disease
4 in a population. However, cross-sectional data cannot assess the effect of lifestyle on the
5 incidence of MetS, and longitudinal cohort studies are therefore needed.
6
7
8

9 10 **Conclusion**

11 Without question, the prevalence rates for several negative health factors were high in the
12 Sami and non-Sami population. Overweight and obesity were common, especially in the case
13 of Sami females. No differences in prevalence of diabetes mellitus was demonstrates between
14 ethnic groups. However, ethnicity appeared to affect diabetes treatment and was significantly
15 more frequent in use among Sami women compared to the non-Sami women. However, the
16 prevalence of MetS were in general high among participants in the SAMINOR study, with the
17 highest prevalence for the European cut off values. The syndrome has important health
18 implication but a cross sectional study cannot be used to validate the best ethnic specific
19 values for WC used in the definition of MetS and more data on this issue must be obtained. In
20 addition, determining preventive initiatives is important in the primary and specialist health
21 care system. These initiatives must be made culture and linguistic specific, in order to reduce
22 differences and improve health status in the whole population.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42 **Acknowledgements**

43 We are indebted to the participants of the SAMINOR study, without whom our research
44 would be impossible. We would also like to thank the staff at the Department of Clinical
45 Chemistry, University Hospital of North Norway, for technical assistance and careful
46 evaluation of blood samples.
47
48
49
50

51 **Summary Box**

52 *What is already known on this subject?*

53
54 In Northern Norway the burden of obesity are especially high among female. Highest
55
56
57
58
59
60

1
2
3 prevalence has been demonstrated among the Sami women. In this study we therefore
4 examined several other risk factors for developing lifestyle diseases.
5
6

7 *What this study adds?*

8
9 This study showed a high prevalence of the metabolic syndrome among the population in
10 north, independent of ethnic belonging. The burden of metabolic risk factors was highest
11 among women, especially Sami women. Self-reported diabetes was between four and five
12 percent which are slightly higher than the national prevalence rate. In the future, obesity and
13 other metabolic risk factors will contribute to increase burden of lifestyle diseases among the
14 Sami population. Two issues are therefore important to emphasize. Firstly, implement
15 preventive interventions in the multicultural communities, as well as highlight research
16 information to inhabitants and local and central authorities. Secondly, follow the health
17 situation in each community with longitudinal studies to evaluate the effect of preventive
18 efforts.
19
20
21
22
23
24
25
26
27
28
29

30 **Contributorship statement**

31 The idea behind the study was conceived by Ann R Broderstad. Both authors participated in
32 the study concept and design. Ann R Broderstad drafted the manuscript. Both authors did the
33 analyses of the tables and figures. Both authors reviewed and approved the final version of the
34 manuscript.
35
36
37
38
39

40 **Conflict of Interest**

41 The authors declare that they have no conflict of interest.
42
43
44

45 **Funding**

46 Funding for this project was provided by the Norwegian Ministry of Health and Care
47 Services.
48
49
50

51 **Data sharing**

52 Extra data is available by emailing ann.ragnhild.broderstad@uit.no
53
54
55
56
57
58
59
60

References

1. Banatvala N, Donaldson L. Chronic diseases in developing countries. *Lancet* 2007; 370(9605): 2076-8.
2. Dale AC, Nilsen TI, Vatten L, Midthjell K, Wiseth R. Diabetes mellitus and risk of fatal ischaemic heart disease by gender: 18 years follow-up of 74,914 individuals in the HUNT 1 Study. *European heart journal* 2007; 28(23): 2924-9.

- 1
2
3 3. Parajuli R, Bjerkaas E, Tverdal A, et al. The increased risk of colon cancer due to
4
5 cigarette smoking may be greater in women than men. *Cancer epidemiology, biomarkers &*
6
7 *prevention : a publication of the American Association for Cancer Research, cosponsored by*
8
9 *the American Society of Preventive Oncology* 2013; 22(5): 862-71.
- 10
11 4. Grundy SM, Brewer HB, Jr., Cleeman JI, et al. Definition of metabolic syndrome:
12
13 Report of the National Heart, Lung, and Blood Institute/American Heart Association
14
15 conference on scientific issues related to definition. *Circulation* 2004; 109(3): 433-8.
- 16
17 5. Simmons RK, Alberti KG, Gale EA, et al. The metabolic syndrome: useful concept or
18
19 clinical tool? Report of a WHO Expert Consultation. *Diabetologia* 2010; 53(4): 600-5.
- 20
21 6. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated
22
23 with the metabolic syndrome: a summary of the evidence. *Diabetes care* 2005; 28(7): 1769-
24
25 78.
- 26
27 7. Goldstein MR, Mascitelli L, Pezzetta F. On treating metabolic syndrome: emphasise
28
29 lifestyle change. *The Lancet Oncology* 2010; 11(5): 415.
- 30
31 8. Ishino K, Mutoh M, Totsuka Y, Nakagama H. Metabolic syndrome: A novel high-risk
32
33 state for colorectal cancer. *Cancer letters* 2012.
- 34
35 9. Russo A, Autelitano M, Bisanti L. Metabolic syndrome and cancer risk. *European*
36
37 *journal of cancer* 2008; 44(2): 293-7.
- 38
39 10. Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in
40
41 worldwide populations. *Endocrinology and metabolism clinics of North America* 2004; 33(2):
42
43 351-75, table of contents.
- 44
45 11. Boyer BB, Mohatt GV, Plaetke R, et al. Metabolic syndrome in Yup'ik Eskimos: the
46
47 Center for Alaska Native Health Research (CANHR) Study. *Obesity* 2007; 15(11): 2535-40.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
12. Liu J, Young TK, Zinman B, Harris SB, Connelly PW, Hanley AJ. Lifestyle variables, non-traditional cardiovascular risk factors, and the metabolic syndrome in an Aboriginal Canadian population. *Obesity* 2006; 14(3): 500-8.
13. Schumacher C, Ferucci ED, Lanier AP, et al. Metabolic syndrome: prevalence among American Indian and Alaska native people living in the southwestern United States and in Alaska. *Metabolic syndrome and related disorders* 2008; 6(4): 267-73.
14. Nystad T, Melhus M, Brustad M, Lund E. Ethnic differences in the prevalence of general and central obesity among the Sami and Norwegian populations: the SAMINOR study. *Scandinavian journal of public health* 2010; 38(1): 17-24.
15. Broderstad AR, Melhus M, Lund E. Iron status in a multiethnic population (age 36-80 yr) in northern Norway: the SAMINOR study. *European journal of haematology* 2007; 79(5): 447-54.
16. Lund E, Melhus M, Hansen KL, et al. Population based study of health and living conditions in areas with both Sami and Norwegian populations--the SAMINOR study. *International journal of circumpolar health* 2007; 66(2): 113-28.
17. Nystad T, Utsi E, Selmer R, Brox J, Melhus M, Lund E. Distribution of apoB/apoA-1 ratio and blood lipids in Sami, Kven and Norwegian populations: the SAMINOR study. *Int J Circumpolar Health* 2008; 67(1): 67-81.
18. WHO technical Report Series 894. Obesity: Preventing and Managing the Global Epidemic. World Health Organization : Geneva, Switzerland, 2000.; 1997. Report by the Secretariat http://apps.who.int/gb/ebwha/pdf_files/EB130/B130_9-en.pdf
19. Janssen I, Peter T, Katzmarzyk PT, Ross R. Body Mass Index, Waist Circumference, and Health Risk Evidence in Support of Current National Institutes of Health Guidelines *Arch Intern Med.* 2002;162(18):2074-2079.

- 1
2
3 20. Lean ME, Han TS, Morrison CE. Waist circumference as a measure for indicating
4 need for weight management. *Bmj* 1995; 311(6998): 158-61.
5
6
7 21. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus
8 and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional
9 report of a WHO consultation. *Diabetic medicine : a journal of the British Diabetic*
10 *Association* 1998; 15(7): 539-53.
11
12 22. Balkau B, Charles MA. Comment on the provisional report from the WHO
13 consultation. European Group for the Study of Insulin Resistance (EGIR). *Diabetic medicine :*
14 *a journal of the British Diabetic Association* 1999; 16(5): 442-3.
15
16 23. Cleeman JI. Executive summary of the third report of the National Cholesterol
17 Education Program (NCEP) expert panel on detection, evaluation, and treatment of high
18 blood cholesterol in adults (adult treatment panel III). *Journal of the American Medical*
19 *Association* 2001; 285(19): 2486 -97.
20
21 24. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome--a new world-wide definition. A
22 Consensus Statement from the International Diabetes Federation. *Diabetic medicine : a*
23 *journal of the British Diabetic Association* 2006; 23(5): 469-80.
24
25 25. Lin WY, Lee LT, Chen CY, et al. Optimal cut-off values for obesity: using simple
26 anthropometric indices to predict cardiovascular risk factors in Taiwan. *International journal*
27 *of obesity and related metabolic disorders : journal of the International Association for the*
28 *Study of Obesity* 2002; 26(9): 1232-8.
29
30 26. Nystad T, Melhus M, Brustad M, Lund E. Ethnic differences in the prevalence of
31 general and central obesity among the Sami and Norwegian populations: the SAMINOR
32 study. *Scand J Public Health*; 38(1): 17-24.
33
34 27. Njolstad I, Arnesen E, Lund-Larsen PG. Cardiovascular diseases and diabetes mellitus
35 in different ethnic groups: the Finnmark study. *Epidemiology* 1998; 9(5): 550-6.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 28. Carr DB, Utzschneider KM, Hull RL, et al. Intra-abdominal fat is a major determinant
4 of the National Cholesterol Education Program Adult Treatment Panel III criteria for the
5 metabolic syndrome. *Diabetes* 2004; 53(8): 2087-94.
6
7
8
9
10 29. van Vliet-Ostapchouk JV, Nuotio ML, Slagter SN, et al. The prevalence of metabolic
11 syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large
12 cohort studies. *BMC endocrine disorders* 2014; 14: 9.
13
14
15
16 30. Ley SH, Harris SB, Mamakeesick M, et al. Metabolic syndrome and its components as
17 predictors of incident type 2 diabetes mellitus in an Aboriginal community. *Cmaj* 2009;
18 180(6): 617-24.
19
20
21
22 31. Russell M, de Simone G, Resnick HE, Howard BV. The metabolic syndrome in
23 American Indians: the strong heart study. *J Cardiometab Syndr* 2007; 2(4): 283-7.
24
25
26
27 32. Jorgensen ME, Bjerregaard P, Gyntelberg F, Borch-Johnsen K. Prevalence of the
28 metabolic syndrome among the Inuit in Greenland. A comparison between two proposed
29 definitions. *Diabet Med* 2004; 21(11): 1237-42.
30
31
32
33 33. Jorgensen ME. Obesity and metabolic correlates among the Inuit and a general Danish
34 population. *Int J Circumpolar Health* 2004; 63 Suppl 2: 77-9.
35
36
37
38 34. Folkehelseinstituttet. Forekomst av diabetes - faktaark med helsestatistikk.
39 <http://www.fhi.no/artikler/?id=70814>
40
41
42 Folkehelseinstituttet; 2015.
43
44
45 35. Velho G, Froguel P, Mann J, Toeller M. Type 2 Diabetes. In: Ekoe J, Zimmet P,
46 Williams R, eds. *The Epidemiology of Diabetes mellitus*. Chichester, England: John Wiley &
47 Sons Ltd; 2001: 133-53.
48
49
50
51 36. Federation ID. *IDF Diabetes Atlas*. 6th edition [internet]. 2013.
52 <http://idf.org/diabetesatlas> (accessed May 4th 2013).
53
54
55
56
57
58
59
60

- 1
2
3 37. Gao XH, Winsey S, Li G, et al. HLA-DR and DQ polymorphisms in bullous
4 pemphigoid from northern China. *Clinical and experimental dermatology* 2002; 27(4): 319-
5
6
7 21.
8
9
10 38. Hutchinson MS, Joakimsen RM, Njolstad I, et al. Effects of Age and Sex on Estimated
11 Diabetes Prevalence Using Different Diagnostic Criteria: The Tromso OGTT Study.
12
13 *International journal of endocrinology* 2013; 613475.
14
15
16 39. Stene LC, Midthjell K, Jennum AK, et al. Prevalence of diabetes mellitus in Norway.
17
18 *Tidsskr Nor Laegrforen* 2004; 124 (11): 1511-4.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

55 **Figure legends**

56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

-----Figure 1 colour -----

-----Figure 1 black and white -----


-----Figure 2 colour -----

-----Figure 2 black and white -----

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Figure 1. Prevalence of different risk markers in participants with Mets. Men.
N= 2008 Euro and N= 1043 NIH



150x133mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 2 . Prevalence of different risk markers in participants with MetS. Women .
N= 2311 Euro and N= 1679 NIH



165x169mm (300 x 300 DPI)



STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	p 1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	P 2
Introductionp 4			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	P 4
Objectives	3	State specific objectives, including any prespecified hypotheses	P 5
Methods			
Study design	4	Present key elements of study design early in the paper	P 5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	p 5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	P 5-6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	p 6 -8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	P 6 -8
Bias	9	Describe any efforts to address potential sources of bias	P 6-8
Study size	10	Explain how the study size was arrived at	P 5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	p 8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	P 8
		(b) Describe any methods used to examine subgroups and interactions	P 8
		(c) Explain how missing data were addressed	P 8
		(d) If applicable, describe analytical methods taking account of sampling strategy	Not applicable
		(e) Describe any sensitivity analyses	Not done
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	P 8-9 and Table 1 Not done
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest	P 8- 9 and Table 1 No missing data in the further analyzes
Outcome data	15*	Report numbers of outcome events or summary measures	Table 1 p 8
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Table 2 p 10, table 3 p 12 fig 1 and 2 p 11 Not relevant
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Not done
Discussion			
Key results	18	Summarise key results with reference to study objectives	P 13 - 16
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	P 16
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	P 14 -16
Generalisability	21	Discuss the generalisability (external validity) of the study results	P 16
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	P 17

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>